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  Summary 
1 Summary 
Photosensitizers (PS) in combination with visible light are approved in 
photodynamic therapy for treatment of several types of cancer. Recent strategies for 
higher bioavailability and the reduction of side effects include PS loaded nanoparticle 
formulations. The subject of the present thesis is the development and 
characterization of gold based and surface modified nanoparticulate drug delivery 
systems for the PS 5,10,15,20-tetrakis(3-hydroxyphenyl)chlorin (mTHPC) for 
intravenous administration. 
Gold nanoparticles (AuNP) with a diameter of 15 nm were prepared and used as 
template for the Layer-by-Layer (LbL) approach. The PS and the negatively charged 
polyelectrolyte (PE) poly(styrene sulfonate) sodium salt (PSS) were complexed with 
a new developed method using freeze-drying resulting in a dramatically increased 
water solubility of the PS. The phototoxicity of the PSS/mTHPC complex in water 
was increased compared to the free mTHPC in ethanol. A drug-multilayer system 
based on the LbL technique utilized the water-soluble complex as anionic layer 
material and poly(allylamine hydrochloride) (PAH) as cationic layer. For the first time, 
a nanoparticulate system with three adsorbed drug layers was prepared. 
The mTHPC-loaded modified AuNP were taken up by cells and the dark toxicity was 
strongly decreased. The mTHPC was released and effective as anticancer drug after 
illumination. In conclusion, the modified AuNP can be considered as promising 
carrier for such types of PS. 
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2 Zusammenfassung 
Photosensibilisatoren (PS) in Kombination mit sichtbarem Licht sind in der 
Photodynamischen Therapie zur Behandlung von Krebs zugelassen. Mit PS 
beladene Nanopartikel (NP) sind eine neue Strategie, um die Bioverfügbarkeit von 
PS zu erhöhen und Nebenwirkungen zu reduzieren. Das Thema dieser Doktorarbeit 
ist die Entwicklung und Charakterisierung von auf Gold (Au) basierten und 
oberflächenmodifizierten nanopartikulären Trägersystemen zur intravenösen 
Verabreichung des PS 5,10,15,20-Tetrakis(3-hydroxyphenyl)chlorin (mTHPC). 
Es wurden AuNP (d = 15 nm) hergestellt, die als Vorlage für die Layer-by-Layer (LbL) 
Technik dienten. Der PS und das negativ geladene Poly(styrol sulfonat) Natriumsalz 
(PSS) wurden mit einer neuen Methode komplexiert, die eine starke Erhöhung der 
Wasserlöslichkeit von mTHPC zur Folge hatte. Die Phototoxizität vom PSS/mTHPC 
Komplex verglichen mit dem freien mTHPC war erhöht. Der Komplex wurde als 
negativ geladenes Schichtmaterial verwendet und Polyallylamin-hydrochlorid (PAH) 
als positives Schichtmaterial, um ein mehrschichtiges Wirkstoffsystem basierend auf 
der LbL Technik aufzubauen. Damit konnte erstmalig die Herstellung eines 
nanopartikulären Systems mit drei Wirkstoffschichten gezeigt werden. 
Die mit mTHPC beladenen und modifizierten AuNP wurden von Zellen 
aufgenommen und die Dunkeltoxizität wurde stark gesenkt. Das mTHPC wurde 
freigesetzt und war nach Bestrahlung wirksam gegen die Krebszellen. 
Zusammenfassend gesagt, sind die modifizierten AuNP ein vielversprechendes 
Transportsystem für diese Arten von PS. 
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  Chapter 1 
The background and the motivation of this thesis was the application improvement of 
the active pharmaceutical ingredient (API) Temoporfin or meta-5,10,15,20-tetrakis-
hydroxyphenyl-chlorin (mTHPC). It is the API of the pharmaceutical product Foscan® 
which is applied intravenously as anticancer drug in photodynamic therapy (PDT). 
But, the bioavailability of mTHPC is very low caused by its water insolubility. A lot of 
the drug is precipitating immediately at the puncture of the injection needle because 
Foscan® is a liquid consisting of mTHPC dissolved in a mixture of ethanol and 
ethylene glycol. The unspecific tissue accumulation of mTHPC is a further challenge. 
Desirable would be the specific accumulation of mTHPC into the cancer cells without 
any accumulation in the healthy tissue. To solve the problems and thereby reduce 
the adverse effects, the usage of nanoparticles is a promising approach. As proof of 
concept, nanoparticles which can be simply identified in water as well as inside of 
cancer cells could be an advantageous choice. Gold nanoparticles (AuNP) have 
those characteristics and even more because AuNP aggregation or AuNP surface 
modification can be easily detected by UV/Vis spectroscopy. In this context, the 
Layer-by-Layer technology is a very comfortable instrument for changing the 
nanoparticle surface, for example for the API loading to the nanoparticle surface or 
an antibody linkage for the specific drug transport to the cancer cells. The following 
thesis will give you a short introduction about those working fields and definitions and 
demonstrate as well as discuss the obtained results. 
3.1 Photodynamic therapy 
Photodynamic therapy (PDT) has now become an established treatment modality for 
several medical indications [1]. Notably, in the cases of skin actinic keratosis [2-4], 
several forms of cancer [5-8], and blindness due to age-related macular degeneration 
[9-11] PDT has been successful. Furthermore, PDT is a photochemical process that 
requires multiple steps to achieve tissue destruction [12]. First, a compound with 
photosensitizing properties which is called photosensitizer (PS) is required. The 
second need is visible light to activate the PS, preferentially in the red region of the 
visible spectrum (λ ≤ 600 nm) to obtain an improved tissue penetration by light. The 
third and last requirement is the presence of oxygen. 1O2, a short-lived product of the 
reaction between an excited PS molecule and oxygen, plays a key role. The reactive 
oxygen species (ROS) that are generated by PDT can kill tumor cells directly by 
apoptosis and/or necrosis. PDT also damages the tumor-associated vasculature, 
leading to tissue deprivation of oxygen and nutrients and consequent tumor infarction 
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[13]. Finally, PDT can activate an immune response against tumor cells [14]. These 
three mechanisms can also influence each other. In contrast to radiation therapy and 
chemotherapy, PDT has a low mutagenic potential and, except for skin phototoxicity, 
few adverse effects [15]. 
The first step in the photosensitizing process is the absorption of a photon by the 
photosensitizer in the ground state and its promotion to the short-lived excited singlet 
state (P1) (Figure 1). The singlet state can relax back into the ground state, resulting 
in the emission of light in the form of fluorescence. Alternatively, it can convert by 
intersystem crossing to the more stable triplet excited state (P3), accompanied by a 
spin conversion. The triplet state is sufficiently long-lived to take part in chemical 
reactions and therefore, the photodynamic action takes place for the most part when 
in the triplet state. 
 
Figure 1: Simplified Jablonski diagram showing porphyrin and oxygen singlet and 
triplet state. P=Porphyrin; * = electronically excited state; 0 = ground 
state; 1 = singlet excited state; 3 = triplet excited state [16]. 
 
There are two types of photodynamic reactions: type I photoprocesses are electron- 
or hydrogen-transfer reactions between the triplet photosensitizer and other 
molecules. These processes produce reactive intermediates that are harmful to cells, 
such as superoxides, hydroperoxyls and hydroxyl radicals, as well as hydrogen 
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peroxide; thereby the photosensitizer usually returns to the ground state (P0). The 
type II photoprocess is an electron spin exchange between the photosensitizer in the 
triplet state and ground-state triplet dioxygen (3O2). This produces a cytotoxic excited 
singlet state of oxygen (1O2) [17], while the photosensitizer returns to its ground state. 
Both, type I and type II reactions cause oxidation of electron-rich biomolecules such 
as unsaturated lipids and amino acids in the cells but 1O2 is regarded as the main 
mediator of phototoxicity in PDT [18]. 
Recent studies have shown that the intracellular lifetime of singlet oxygen is ~3 µs in 
a viable, metabolically active cell [19]. The resulting intracellular diffusion coefficient 
of singlet oxygen has been estimated to be 2 – 4 x 10-6 cm2 s-1 means that the spatial 
domain of intracellular singlet oxygen activity will likely have a spherical radius of 
approximately 100 nm [20]. This short singlet oxygen lifetime and resulting diffusion 
distance makes PDT a highly selective form of cancer treatment due to the localized 
effect it produces. 
The mechanism of action of PDT is dependent on various factors including cell 
genotype [21, 22], PDT dose [22], intracellular adenosine triphosphate levels [23], 
and photosensitizer localization. Most PDT sensitizers tend not to accumulate in 
nuclei; therefore, PDT is unlikely to induce DNA damage, mutations and 
carcinogenesis [24]. Mitochondrial-localizing photosensitizers are likely to induce 
apoptosis, while plasma membrane-localizing sensitizers are more likely to cause 
necrosis when exposed to light [25]. In general, the mode of cell death switches from 
apoptotic to necrotic cell death when the intensity of the insult is excessive, 
producing rapid cell lysis rather than an organized programmed cell death effect [26]. 
3.2 Photosensitizers 
Photosensitizing drugs have been known and applied in medicine for several 
thousand years. However, the scientific basis for such use was vague or non-existent 
before about 1900 [15]. Photosensitizers are generally classified as porphyrins and 
nonporphyrins. An overview of photosensitizing drugs can be seen in Figure 2. 
Porphyrin-derived photosensitizers are further classified as first, second, or third 
generation photosensitizers. First generation photosensitizers include 
hematoporphyrin derivatives and Photofrin. A number of second generation 
photosensitizers have been developed to alleviate certain problems associated with 
first generation molecules such as prolonged skin photosensitization and suboptimal 
tissue penetration [27]. These second generation photosensitizers absorb light at a 
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longer wavelengths and cause significantly less skin photosensitization post-
treatment compared with first generation compounds. In addition, second generation 
compounds must be at least as efficient in eradicating tumors as Photofrin, the 
current gold standard for PDT [28]. Second generation photosensitizers bound to 
carriers such as antibodies, liposomes, and nanoparticles for selective accumulation 
in tumor tissue are referred to as third generation photosensitizers and currently 
represent an active research area in the field [29]. 
 
 
Figure 2: Classification of photosensitizers as (a) porphyrin-based or (b) 
nonporphyrin-based molecules. 
 [17] A. E. O'Connor, W. M. Gallagher, A. T. Byrne. Porphyrin and nonporphyrin 
photosensitizers in oncology: Preclinical and clinical advances in photodynamic 
therapy. Photochemistry and Photobiology. 2009; 85 (5), 1053-1074. Copyright Wiley-
VCH Verlag GmbH & Co. KGaA. Reproduced with permission. 
 
PDT with porphyrin derivatives as photosensitizing drugs was developed from about 
1960 [30]. The basic structural formulas of some porphyrins are presented in Figure 
3. Porphyrins are a class of tetrapyrroles, which comprise a major component of 
hemoglobin and myoglobin, two O2-binding proteins found in human blood. 
Porphyrins are essential for the biological activity of a living organism. These 
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molecules posses a highly conjugated, heterocyclic macrocycle and may also contain 
a central metallic atom such as iron (heme as part of hemoglobin) or magnesium 
(chlorophyll). The presence of a 22 π electron system gives rise to their long 
wavelength absorption. As a result, porphyrins have attracted the attention of 
researchers globally for application as photosensitizing agents in medicine [31]. 
 
Figure 3: Basic structure of some photosensitizers. 
[32] K. Berg, P. K. Selbo, A. Weyergang, A. Dietze, L. Prasmickaite, A. Bonsted, B. O. 
Engesaeter, E. Angell-Petersen, T. Warloe, N. Frandsen, A. Hogset. Porphyrin-related 
photosensitizers for cancer imaging and therapeutic applications. Journal of 
Microscopy. 2005; 218 (2), 133-147. Copyright Wiley-VCH Verlag GmbH & Co. KGaA. 
Reproduced with permission. 
 
In this study, Temoporfin was used. This drug, which is also known as Foscan®, 
meso-tetra-hydroxyphenyl-chlorin, or meta-5,10,15,20-tetrakis-hydroxyphenyl-chlorin 
is a member of the chlorin family. It is a commercial available and widely utilized 
photosensitizer for PDT [33]. Temoporfin is among the most potent PS’s as it yields 
an extraordinary amount of singlet oxygen at 652 nm and has a molar extinction 
coefficient of 3 x 104 M-1 cm-1 [17, 34]. It is a hydrophobic second generation 
photosensitizer and has been shown to have a plasma half-life time in humans of 
~45-65 h [33]. Foscan® was approved in Europe for the palliative treatment of neck 
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and head cancers in 2001 [17]. In general dosing is between 0.1 and 0.2 mg/kg and 
illumination requires only 20 J cm-2. Moreover, drug doses and light intensity required 
to obtain a similar response to Photofrin are up to 100 times lower due to the superior 
photophysical properties and higher singlet oxygen yield of Foscan® [34]. The 
mechanism of action of Temoporfin is via direct tumor cell toxicity as well as vascular 
damage. In addition, the drug has been shown to preferentially accumulate in the 
tumor cells of orthotopic brain tumor implants, with a tumor to normal brain tissue 
ratio of 100:1, thus making Temoporfin-mediated PDT a highly selective form of 
cancer therapy [35-37]. Treatment time is only a few minutes. However, significant 
pain can occur during this time. Further, clinically, it takes about 4 days to achieve 
accumulation in the tumor and clearance from normal tissue for treatment to begin. 
For the first day post infusion even very dim light can lead to severe skin 
photosensitivity. Illumination itself must be precise with significant effort to block light 
from reaching normal tissues as even reflected light is potent enough to generate a 
photodynamic reaction in unwarranted regions. A major drawback of the drug is 
prolonged skin photosensitivity, which can last up to 6 weeks, but usually about 2-4 
weeks following treatment. A significant body of clinical literature shows Foscan® can 
work well under a number of different treatment protocols. Excellent response for 
head and neck cancer patients has been reported, including tumors of the lip and 
oral cavity [38-42]. 
3.3 Polyelectrolytes 
The term polyelectrolyte describes a polymer system that is composed of a 
macromolecule consisting of largely charged monomer units, and low-molecular 
counterions ensuring electroneutrality. Well-known examples are DNA, RNA, 
polysaccharides, and proteins. Depending on the charge, one can distinguish 
between polycations and polyanions. A special case of polyelectrolytes are the 
polyampholytes, which contain positively as well as negatively charged functional 
groups in the polymer chain. Polyelectrolytes dissolve in aqueous media under 
dissociation in a charged polymer chain and counterions, even if the polymer 
backbone is hydrophobic. The respective degree of dissociation and thus the charge 
density depends on the strength of the polyacid or polybase. According to their 
acid/base strength polyions can be classified into: (1) strong polyelectrolytes that are 
almost completely dissociated over a broad pH range as their charge density is 
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nearly independent of the solution pH and (2) weak polyelectrolytes whose degree of 
dissociation α strongly varies with the pH value [43]. 
As polyelectrolytes combine the properties of polymers and electrolytes, the 
theoretical description of their structure in aqueous media is rather complex. Long 
flexible chains can acquire a number of different conformations, therefore their shape 
and size can be treated only statistically. But it is known that if the polymer is strongly 
charged, the polyion chain is characterized by a high expansion or stretching 
compared to neutral polymers due to the strong electrostatic repulsion of the charged 
segments [43]. 
The mixing of a solution containing a polyanion (├A- c+)n with a solution of a 
polycation (├C+ a-)m leads to the formation of polyelectrolyte complexes (├A- +C┤)x, 
[44], and can be described by the following chemical equation: 
(├A- c+)n + (├C+ a-)m  ⇄  [(├A- +C┤)x (├A- c+)n-x (├C+ a-)m-x] + x c+ + x a- [43] 
The driving force of this process is the gain in entropy due to the release of 
counterions, c+ and a-, which are initially located in the vicinity of the polyion chains. 
Besides electrostatic interactions between the charged species, also other factors 
such as hydrophobic interactions or hydrogen bonding may contribute to the complex 
formation. Usually complex formation between polyelectrolytes of similar chain length 
yields highly aggregated particles, which consist of a neutralized hydrophobic core 
and a shell of the excess component, which stabilizes particles against further 
coagulation. Macroscopic flocculation of the system occurs at 1 : 1 charge 
stoichiometry. Figure 4 depicts the two borderline cases for the structure of the 
polyelectrolyte complex precipitates: the ladder structure with fixed ionic cross-links 
between two oppositely charged chains and the “scrambled egg” structure with 
statistical charge compensation. The real structure is somewhere between, but 
mostly nearer to the “scrambled egg” structure. 
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Figure 4:  Limiting structures of polyelectrolyte complex precipitates. Left: Ladder 
model. Right: “Scrambled egg” model. 
[45] H. Dautzenberg, W. Jaeger, J. Kötz, B. Philipp, C. Seidel, D. Stscherbina. 
Polyelectrolytes: Formation, Characterization and Application. Munich: Hanser 
Publishers 1994. Copyright Carl Hanser Verlag GmbH & Co. KG. Reproduced with 
permission. 
 
The complex formation proceeds very fast with polymer diffusion being the rate-
limiting step. After collision the formed polyanion-polycation complexes are “frozen” 
in a non-equilibrium state at very low salt concentrations. In contrast, in the presence 
of external salt the back reaction of complex formation (see above) becomes more 
favored, so that intramolecular and intermolecular rearrangements to an equilibrium 
structure can occur on a reasonable timescale. Even polyion exchange reactions 
have been observed at increased ionic strength [46]. 
3.4 Layer-by-Layer technique (LbL) 
In the early 1990s Decher et al. developed a method that applies the electrostatic 
complex formation between polyanionic and polycationic compounds to build up 
organized multilayered thin films [47]. During this Layer-by-Layer (LbL) template 
assisted assembly [44, 48-51], which was already proposed by Iler in 1966 [52], a 
charged solid substrate is alternately immersed in aqueous solutions of positively and 
negatively charged polyelectrolytes (Figure 5). The polyelectrolyte molecules adsorb 
to the oppositely charged surface until the deposition is limited by electrostatic 
repulsions. Before the adsorption of next layer, the substrate is washed to remove 
excess polyelectrolyte. These steps can be repeated limitlessly and films with up to 
1000 layers have been successfully built [53]. The thickness of one layer varies 
between several angstroms and a few nanometers depending on the deposition 
conditions [43]. 
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Figure 5: Simplified principle of LbL technique. 
[44] G. Decher, J. B. Schlenoff “Multilayer thin films: Sequential assembly of 
nanocomposite materials.” G. Decher, 1 ed. Weinheim: Wiley-VCH, p. 4, 2003. 
Copyright Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission. 
 
The main advantage of this technique is its wide versatility relating to the used layer 
material. Possible polyelectrolytes are synthetic polyelectrolytes [54], 
polysaccharides [55], polypeptides [56], proteins [57], enzymes [54, 58, 59] and 
nucleic acids [59, 60]. This large choice of layer material allows surface coatings with 
interesting chemical, biological, optical, electronic, magnetic, adhesive or anti-
bacterial properties giving rise to a variety of possible applications in different fields 
[44]. Besides of electrostatic interactions also other possibilities are available to built 
up multilayer systems such as hydrogen bonding or covalent interactions [61]. 
According to the zone model of Ladam et al. [62] multilayers can be subdivided into 
three domains (Figure 6):  
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Figure 6: The zone model for the growth of polyelectrolyte multilayers. The first 
layer pair is shown on the left and a film consisting of several layers is 
shown on the right. Only zone II grows with increasing numbers of 
layers. On the very right is depicted how the three zones can be 
correlated with a model consisting of individual but strongly overlapping 
layers. 
[44] G. Decher, J. B. Schlenoff “Multilayer thin films: Sequential assembly of 
nanocomposite materials.” G. Decher, 1 ed. Weinheim: Wiley-VCH, p. 19, 2003. 
Copyright Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission. 
 
Zone I, II, and III would normally differ in both chemical composition and in structure. 
Simplified, zone II is neutral and the zones I and III are charged. Depending on the 
charge density of the substrate and on the substrate roughness, varying amounts of 
small counterions may be present in zone I. Counterions are ubiquitous in zone III 
because the adsorption of every layer leads to an overcompensation of the original 
surface charge and the newly created excess charge of the last deposited layer with 
polymer chains dangling into the solution must be accompanied by the presence of 
small counterions [44]. 
Note that the borders between the zones I and II and between zones II and III are not 
sharp but gradual. At present it is not known how many layers actually contribute to 
zone I and III, but this should be a function of the substrate, of the chemical structure 
of the respective polyion pair used for the deposition and of the deposition conditions 
[44]. 
When the multilayer is fabricated, at first, only zone I and III exist. Initially, there will 
probably a situation in which zones I and III will not have reached their final thickness 
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and the transition between them may occur directly without forming a zone II. As 
more layers are added they will reach their final thickness and composition while 
zone II starts to grow [44].  
Without zone II the growth characteristic of such a layer system is exponentially. 
During this growth phase the thickness of zone III steadily increases leading to an 
increased penetration depth of the diffusing polyion (first stage in Figure 6), and thus 
a higher amount of polymer being deposited per adsorption step. When the film 
reaches a critical thickness the diffusing polyelectrolyte cannot penetrate the whole 
film depth anymore (from second stage in Figure 6 onwards) and zone II develops. 
As the penetration depth (zone III) stays constant from there on, an equal amount of 
polyelectrolyte is adsorbed per bilayer leading to a transition from the exponential to 
the linear growth regime [44].  
For some polyelectrolyte pairs, such as the most frequently studied poly(allylamine 
hydrochloride) (PAH) and poly(styrene sulfonate) (PSS) at low ionic strength and 
temperature, zone III extends only over one or two polyelectrolyte layers, leading to a 
linear layer growth right after the initial build-up zone [43]. On the contrary, other 
polyion combinations can diffuse deeply into the film [63], so that the exponential 
growth passes into a linear growth only after 25 or more layers (e.g. poly(L-
lysine)/hyaluronic acid) [43, 64, 65]. 
In zone II, most of the charged polymer segments are intrinsically compensated by 
oppositely charged polyion segments [66, 67]. Any rearrangement of the chains is 
kinetically hindered as they are highly interconnected with each other by multiple 
ionic bonds. In contrast, due to the charge overcompensation the less densely 
packed zone III contains a substantial amount of counterions showing a gradient of 
increasing concentration towards the water interface. Although being quite 
hydrophobic in the interior polyelectrolyte multilayers include typically 40 - 60% water 
[68, 69]. Even in the dried state the films are strongly hydrated: Water contents of 
10 - 20% have been found [70, 71]. Multilayers are permeable for small molecules 
[72, 73]. Depending on the layer thickness, the polyelectrolytes used for preparation 
and the environmental conditions, their cut-off size can be precisely tuned. 
Furthermore due to their bipolar structure multilayer membranes exhibit a high 
selectivity for differently charged ions or even polar vs. non-polar compounds making 
them attractive as separation membranes for ions, gases, and solutes [44, 74-78]. 
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In addition to the type of polyions, multilayer growth was found to be affected by a 
range of other parameters such as the ionic strength [68, 70, 79, 80], and the type of 
salt of the deposition solution [79, 81], the polymer charge density varied either by 
charge dilution in copolymers [80, 82, 83], or by changing the pH of weak polyion 
solutions [84, 85], the type of solvent [79, 86], temperature [64, 87-89], adsorption 
time [79, 90], polymer concentration [79], and the molecular weight of the polyions 
[91, 92]. Both an increase of ionic strength and an increase of temperature were 
shown to increase the thickness of the deposited layers, at the same time extending 
the exponential growth regime [64]. At higher ionic strength polyions in solution adopt 
a more coiled conformation with a lower radius of gyration due to screening of the 
charges. Upon adsorption they retain their solution conformation and therefore 
occupy a lower surface area per chain and in parallel lead to thicker layers with an 
increased internal and external roughness [43, 70]. 
Not only the growth of polyelectrolyte multilayers can be influenced by a number of 
different parameters, also after preparation the films are sensitive to a change of the 
external conditions such as humidity [93, 94], solvent [95], pH [96, 97], ionic strength 
[98, 99], or temperature [100, 101]. In the fabrication of multilayers adsorbed to 
nanoparticles, additional aspects have to be considered such as nanoparticle 
concentration to polyelectrolyte concentration to avoid coagulation of partly covered 
particles [102]. Additionally, the corresponding timescales of adsorption and 
coagulation are crucial for successful multilayer formation on single colloids [43, 50]. 
3.5 Nanoparticles in medicine 
The regulation of engineered nanoparticles requires a widely agreed definition of 
such particles. Several definitions for nanoparticles were provided by researchers, 
institutes, and governments. For example, the Joint Research Centre of the 
European Commission defines nanoparticles as particles in a size range between 1 
and 100 nm. The National Nanotechnology Initiative (NNI), on the other hand, 
defines nanotechnology as the understanding and control of matter at dimensions of 
roughly 1 to 100 nanometers, where unique phenomena enable novel applications. 
Furthermore, they emphasize that at the nanoscale the physical, chemical, and 
biological properties of materials differ in fundamental and valuable ways from the 
properties of individual atoms and molecules or bulk matter [103]. The National 
Cancer Institute gives the following nanoparticle definition: A particle of that is smaller 
than 100 nanometers. In medicine, nanoparticles can be used to carry antibodies, 
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drugs, imaging agents, or other substances to certain parts of the body. 
Nanoparticles are being studied in the detection, diagnosis, and treatment of cancer 
[104]. In general, nanoparticles can be defined as particles with sizes between about 
1 and 100 nm that show properties that are not found in bulk samples of the same 
material [105].  
Nanoscale drug delivery systems are emerging technologies for the rational delivery 
of chemotherapeutic drugs in the treatment of cancer. Their use offers improved 
pharmacokinetic properties, controlled and sustained release of drugs, and more 
importantly, lower systemic toxicity [106]. A wide variety of nanoparticles e.g., 
inorganic nanoparticles [107-109], polymeric nanoparticles [110-112], solid lipid 
nanoparticles [113-115], liposomes [116-120], nanocrystals or quantum dots [121, 
122], nanotubes [123, 124], and dendrimers [125, 126] exist already, and diverse 
methods of synthesis have been developed. Nevertheless, only a few numbers of 
commercial available nanoparticle formulations are on the open market today. One of 
five formulations is the liposomal formulation Doxil® with doxorubicin as active 
pharmaceutical ingredient and another one is the albumin-nanoparticle-based 
Abraxane® with paclitaxel as active pharmaceutical ingredient [127]. 
Mainly two advantages are responsibly for the increased interest of nanoparticles in 
research. First, the larger size of nanoparticles relative to small molecule drugs, can 
avoid first-pass clearance from the bloodstream if intravenously administrated [127]. 
Second, nanoparticles can selectively accumulate in tumor tissue via the enhanced 
permeability and retention effect, also known as passive targeting [128]. 
Furthermore, an active targeting of nanoparticles is possible, which is characterized 
by attachment of specific ligands such as peptides, antibodies, aptamers, or small 
molecules to the nanoparticle surface [129, 130]. 
3.6 Gold nanoparticles (AuNP) in medicine 
AuNP are characterized by their excellent optical and photoelectrical properties. 
Furthermore, studies have confirmed that AuNP are non-toxic [131] but nevertheless 
this is a size-dependent parameter [132]. Additional advantages of AuNP are their 
simple preparation, long stability, and possibility of surface modification by place-
exchange reactions [133] or LbL technology [134]. 
The control of AuNP size, shape, and surface modification is desirably because 
these properties influence the pharmacokinetic parameters of AuNP [127, 135]. To 
synthesize monodisperse distributed and spherical AuNP, one method is the two-
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phase Brust-Schiffrin method [136], in which aqueous sodium borohydride is used to 
reduce AuCl4¯ in toluene in the presence of stabilizing thiols. Another reliable method 
is the older Turkevich synthesis [137], where gold salt is boiled together with citrate 
to get 10 - 100 nm water-soluble particles (Figure 7 a). The preparation of rod-
shaped AuNP in different aspect-ratios can also be carried out (Figure 7 c and d). 
 
c d
ba a 
Figure 7: (a) Transmission electron micrographs of Au nanospheres, (b) 
Photographs of colloidal dispersions of AuAg alloy nanoparticles with 
increasing Au concentration, (c) Transmission electron micrographs of 
nanorods, (d) Photographs of colloidal dispersions of Au nanorods of 
increasing aspect ratio. 
[138] L. M. Liz-Marzan. Nanometals: Formation and color. Materials Today. 2004; 7 
(2), 26-31. Copyright Elsevir B.V. Reproduced with permission. 
 
In medicine, AuNP can be used as drug delivery system [139], in diagnostic [140], 
and for detection of proteins and nucleic acids [141, 142]. The focus of this study will 
be on drug delivery systems, which provide positive attributes to a free drug by 
improving solubility, in vivo stability, and biodistribution.  
Following, two commercial examples for the application of AuNP in medicine are 
named. Aurimune, a pegylated AuNP formulation with surface attached tumor 
necrosis factor of the company CytImmune Science against solid tumors for 
intravenous application is the first AuNP formulation in Phase I/II of clinical trials 
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[127]. Moreover, a lot of patents exist in the field of AuNP in connection with drug 
carriers. One commercial home pregnancy test even uses AuNP to form the pink 
line, which is actually made of 40 nm AuNP functionalized with a human antibody 
[143, 144]. 
A further promising application of AuNP is the photothermal cancer therapy caused 
by the ability of AuNP to convert absorbed light (λ ~ 520 nm) efficiently into localized 
heat [140]. Several articles were already published about AuNP as drug delivery 
system for small drug molecules and biomolecules such as nucleic acids and 
proteins [134, 139, 145]. Schneider et al. developed a multifunctional, AuNP based, 
and multilayered drug delivery system as a kind of template for different diseases 
(Figure 8) [146]. As a proof of concept, they prepared AuNP with a diameter of 
around 13 nm, attached three layers of PAH and two of PSS, and covalent attached 
a terpolymers on the PAH surface to allow the covalent bond of the drug doxorubicin 
on the nanoparticle surface. This promising and multifunctional model raises hope for 
more efficient tumor therapy with reduced side effects in the future. 
 
Figure 8: Schematic representation of a multiple coated and AuNP-based 
rich, G. Decher. Multifunctional cytotoxic stealth 
erlag GmbH & Co. KGaA. Reproduced with permission. 
 
complex drug delivery system. 
[146] G. F. Schneider, V. Subr, K. Ulb
nanoparticles. A model approach with potential for cancer therapy. Nano Letters. 
2009; 9 (2), 636-642. 
Copyright Wiley-VCH V
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3.7 Aim of this thesis: 
 
In this thesis, the main goal was to develop a nanoparticulate and Layer-by-Layer 
(LbL) surface modified carrier system for the intravenous delivery of the water 
insoluble photosensitizer (PS), 5,10,15,20-tetrakis(3-hydroxyphenyl)chlorin 
(mTHPC), for the treatment of head and neck cancer by photodynamic therapy 
(PDT). The LbL technique was carried out with the positively charged polyelectrolyte 
(PE) poly(allylamine hydrochloride) (PAH) and the negatively charged PE 
poly(styrene sulfonate) sodium salt (PSS) 
 
 
The major aims of this thesis were: 
 
 
1.) Preparation and characterization of mTHPC loaded AuNP and their stability in 
biological environment like different cell culture media. 
 
 
2.) Application of the LbL technology to incorporate the drug mTHPC into the 
polyelectrolyte layer system around the AuNP cores.  
 
 
3.) Adjustment of the mTHPC concentration in relation to one carrier by 
preparation of drug-multilayers attached to the AuNP templates. 
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Abstract: 
Photosensitizers are used in photodynamic therapy (PDT) as promising treatment 
method of solid tumors. To avoid low bioavailability as well as side effects caused by 
the insolubility of the photosensitizers in water, we have prepared a water soluble 
complex consisting of the water insoluble photosensitizer 5,10,15,20-tetrakis(3-
hydroxyphenyl)chlorin (mTHPC) non-covalently attached to the polyelectrolyte 
poly(styrene sulfonate) sodium salt (PSS). The complex preparation with the highest 
drug loading was carried out by freeze-drying an ethanolic/aqueous (1:1 v/v) mixture 
of both compounds. The complexation efficiency determined by UV/vis measurement 
and CHNS elemental analysis was 11±2 monomer units or 4-ethyl(styrene sulfonate) 
sodium salt (ESS) units of PSS to complex one mTHPC molecule independent of 
PSS molecular weight. The photophysical characterization resulted in a decreased 
singlet oxygen quantum yield of the complex compared to free mTHPC but in an 
increased phototoxicity. No toxicity of PSS could be observed in vitro indicating that 
the PSS/mTHPC complex has great prospects to become a potential drug delivery 
system for mTHPC, especially due to its simple and quick preparation. 
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4.1 Introduction 
Photodynamic therapy (PDT) is an established minimally invasive therapeutic 
modality approved for clinical treatment of several types of cancer and non-
oncological disorders [1, 2]. PDT treatment is based on the presence of a drug with 
photosensitizing properties (photosensitizer) combined with visible or infrared light 
and tissue oxygen. The activation of the photosensitizer by light generates reactive 
oxygen species, such as singlet oxygen, responsible for direct or indirect destruction 
of tumor cells. The cell death occurs mainly by the induction of apoptosis and 
necrosis [3, 4]. 
The application of PDT technique clearly requires systemic delivery of 
photosensitizers. Unfortunately, the extended delocalized aromatic π-electron system 
characterizing photosensitizers generally makes them highly hydrophobic and thus 
poorly water soluble and prone to aggregation and precipitation in aqueous solution 
[5-7]. The resulting disadvantage is the decrease of their ability to efficiently generate 
singlet oxygen in combination with multifarious other intrinsic drawbacks such as the 
poor bioavailability combined with unfavorable biodistribution, the non-selective 
tumor specificity, and respectively undesirable side effects such as prolonged skin 
phototoxicity of up to two weeks and damage to surrounding healthy tissues [8, 9]. 
To solve the problems, a lot of promising studies were carried out using 
photosensitizer conjugates [5, 10] or nanoparticles [11-14] as drug delivery systems 
with the aim to increase the water solubility of the photosensitizers and the specificity 
to the tumor tissue caused by receptor–mediated endocytosis [15] or the EPR effect 
[16]. Nevertheless, the elaborated and time-consuming preparation is a big 
disadvantage for the nanoparticulate-based approaches. Whereas, the drawback of 
the photosensitizer conjugates is caused by the covalent bond between the drug and 
the excipient resulting in a reduced drug activity and delayed release [10, 12]. For 
photosensitizers, a fast release is aspired to avoid side effects [13]. 
As a simple and novel carrier system, we formed a coadsorbate between the 
photosensitizer and the polyelectrolyte poly(styrene sulfonate) (PSS). The 
advantages of PSS are the very good water solubility in combination with the 
hydrophobic π-system allowing for non-covalent attachment of the photosensitizer, 
and the established administration for pharmaceutical applications [17]. As drug was 
used the second generation photosensitizer [12] 5,10,15,20-tetrakis(3-
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hydroxyphenyl)chlorin (mTHPC) and its low cost model drug 5,10,15,20-tetrakis(3-
hydroxyphenyl)porphyrin (mTHPP) for the physico-chemical characterization 
(Scheme 1). The drug was non-covalently coupled to PSS by H-bonds and π−π 
interaction. The preparation technique, the influence of the PSS molecular weight, 
the complexation efficiency, and the photophysical properties of the resulting 
PSS/mTHPC coadsorbates were investigated in this study. The overall preserved 
photosensitizing ability after complexation could be demonstrated for PSS/mTHPC in 
vitro.  
 
Scheme 1: Structural formula of mTHPP and PSS/mTHPC complex (4.3 kDa). 
 
4.2 Materials and methods 
4.2.1 Materials 
The 5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrin, mTHPP, (MW 678.73 g/mol) and 
5,10,15,20-tetrakis(3-hydroxyphenyl)chlorin, mTHPC, (MW 680.75 g/mol) seen in 
Scheme 1 were kindly provided by biolitec AG (Jena, Germany). Poly(styrene 
sulfonate) sodium salt (PSS) (MW 0.21, 4.3, 13, 32.9, and 152 kDa) was purchased 
from Sigma-Aldrich (Steinheim, Germany). PSS with MW 1.10, and 1.92 kDa was 
purchased from Polymer Standards Service GmbH (Mainz, Germany). The water 
used in all experiments was prepared in a Millipore Milli-Q purification system 
(resistivity higher than 18.0 MΩ/cm). 
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4.2.2 Methods 
4.2.2.1 PSS/mTHPP complexation efficiency 
A fixed mass of mTHPP (77 µg) in 2 mL ethanol was added to different masses of 
PSS with molecular weight of 4.3 kDa (92, 184, 500, 922, 1844, 5001 mg) in 2 mL 
water, to check if complex formation occurs. After mixing, the solution was freeze-
dried in a Christ Alpha 2-4 LSC (Christ GmbH, Osterode, Germany). The lyophilisate 
was suspended in water and centrifuged for 35 min at 16,098 g with a table 
centrifuge, Hettich Rotina 420 R (Hettich GmbH & Co. KG, Tuttlingen, Germany). 
The supernatant was filtered to remove the free mTHPP. The pellet of centrifugation, 
the filters and all other materials which were in contact with the complex mixture were 
rinsed out with ethanol, which was collected and pooled to determine the 
concentration of free or not complexed mTHPP. The concentration of mTHPP in 
ethanol was obtained by UV/vis spectroscopy (5 relevant peaks: λex ∈ {416, 512, 
546, 589, 645} nm) (PerkinElmer Lambda 35, PerkinElmer LAS, Rodgau, Germany). 
The mass of mTHPP in ethanol subtracted from initial weight of mTHPP (77 µg) is 
the mass of the mTHPP transferred to the aqueous phase in a complex with PSS. 
To determine how many monomer units (4-ethyl(benzene sulfonate) sodium salt 
(ESS) units) of PSS are necessary to complex one mTHPP molecule, around 50 mg 
of the corresponding PSS (MW 0.21, 1.10, 1.92, 4.3, 13, 32.9, and 152 kDa) was 
dissolved in 5 mL water. Each aqueous solution of PSS was mixed with 20 mg of 
mTHPP in 5 mL ethanol. The mixtures were freeze-dried and purified like described 
before. The efficiency of complexation was determined by UV/vis measurement. 
To investigate additional procedures for successful complex formation between PSS 
and mTHPP further experiments were carried out. Freeze-drying with a mixture of 
PSS and mTHPP in water instead of a water/ethanol, simple stirring of both 
compounds in water and also the evaporation of an ethanolic/aqueous (1:3 v/v) 
solution with PSS an mTHPP were checked for their complexation efficiency. 
 
4.2.2.2 Preparation of PSS/mTHPC complex 
A similar procedure was before described by Reum et al [18] for mTHPP loaded to 
colloidal gold. In this study, however, we used the approved drug for head and neck 
cancer mTHPC. 50.14 mg (7.37 µmol) of PSS (MW = 4,300 g/mol) was dissolved in 
15 mL water. 21.75 mg (31.95 µmol) of mTHPC was dissolved in 15 mL ethanol. 
Both solutions were mixed and freeze-dried in a Christ Alpha 2-4 LSC (Christ GmbH, 
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Osterode, Germany). To obtain maximum complexation, the drug mTHPC was used 
in excess. Hence, not all of the drug could be complexed with the PSS necessitating 
a purification step after the freeze-drying. Therefore, the lyophilisate was suspended 
in 50 mL of water and centrifuged for 35 min at 16,098 g with a table centrifuge, 
Hettich Rotina 420 R (Hettich GmbH & Co. KG, Tuttlingen, Germany). The 
supernatant was filtered and refilled with water to 50 mL. The pellet of centrifugation, 
the filters and all other materials which were in contact with the complex mixture were 
rinsed out with 50 mL ethanol which was collected to determine the concentration of 
free or not complexed mTHPC. The concentration of mTHPC in ethanol was 
obtained by UV/vis spectroscopy (5 relevant peaks: λex ∈ {417, 517, 542, 597, 
650} nm) (PerkinElmer Lambda 35, PerkinElmer LAS, Rodgau, Germany). The mass 
of mTHPC in ethanol subtracted from the initial weight of mTHPC (21.75 mg) is the 
mTHPC mass in water complexed with PSS. The concentrations of PSS (4.3 kDa) 
and mTHPC complexed in water were determined directly by CHNS elemental 
analysis. 
 
4.2.2.3 Characterization of PSS/mTHPC coadsorbate 
4.2.2.3.1 Docking study 
Molecular docking simulations were carried out to simulate, predict, and better 
understand the interactions between the drug (mTHPC) and the polyelectrolyte 
carrier (PSS). All calculations were performed on Intel(R) Core(TM) 2 Duo CPU 3.00 
GHz running Linux CentOS 5.3. 3-dimensional structures of both mTHPC and PSS 
were generated using MOE2008.10 (Chemical Computing Group Inc., Montreal, 
Canada). For simplification, the PSS molecule was depicted as a nine monomer unit. 
The structures were energy minimized with the MMFF94 force field as implemented 
in MOE. Ionization states and hydrogen positions were assigned using the protonate 
3D utility of MOE. AutoDock- Tools4 [19] was used for input files preparation and 
AutoDock Vina, version 1.0 [20] was used to dock mTHPC in the structure of PSS: 
60 binding modes were produced with an exhaustiveness parameter of 100. 
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4.2.2.3.2 CHNS elemental analysis 
The elemental analysis of freeze-dried PSS (4.3 kDa), mTHPC, and PSS/mTHPC 
complex was performed. Carbon, hydrogen, nitrogen, and sulfur were analyzed by 
universal elemental analyzer vario El III (Elementar Analysensysteme GmbH, Hanau, 
Germany). Samples were weighed into tin boats, compressed and taken to the auto 
sampler, where they are dropped into the combustion tube automatically. Calibration 
curves of sulfanilic acid as reference compound (C: 41.6, H: 4.1, N: 8.1 and S: 18.5 
wt-%) were compiled by manufacturer and daytime factor measurements were 
repeated six times with weighed samples of about 5 mg. Each freeze-dried sample 
was measured three times. The theoretical calculation of the percentage of elements 
of mTHPC and PSS was done on the basis of their structural formula 
(Supplementary data). 
 
4.2.2.3.3 UV-visible spectroscopy measurements 
The amounts of mTHPP and mTHPC in the drug complex were determined indirectly 
based on UV/vis spectroscopy. Therefore, the concentration of mTHPP and mTHPC 
in the organic solution (ethanol) was determined (see 2.2.1. and 2.2.3.) from which 
the aqueous concentrations could be calculated. All measurements were carried out 
in 1 cm quartz cuvettes with the Perkin Elmer Lambda 35 Spectrophotometer (Perkin 
Elmer LAS, Rodgau, Germany). 
 
4.2.2.3.4 Singlet oxygen measurements 
Time resolved singlet oxygen luminescence measurements were carried out using a 
nanosecond ND3+-YAG laser (BM Industries, Evry Cedex, France) with an attached 
optical parametric oscillator (OPO, Ekspla, 420-2500 nm). For the spectral selection 
of the emitted light an 800 nm edge filter and a 1270 nm interference filter was used. 
The singlet oxygen emission was detected using a liquid nitrogen cooled Ge-PIN 
diode (North Coast, Inc.; Santa Rosa CA). The PSS/mTHPC complex was dissolved 
in D2O and the mTHPC was dissolved in ethanol The optical density was adjusted to 
0.2 at the excitation wavelength of 548 nm. Rose Bengal served as reference 
standard for the determination of singlet oxygen quantum yield (QY = 0.76). 
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4.2.2.3.5 Photodynamic activity and cytotoxicity 
To determine the phototoxicity of pure mTHPC and the polyelectrolyte complex, 
Jurkat cells (clone E 6-1 human acute T-cell leukaemia) were cultured in RPMI 1640 
medium with L-glutamine (PAA, Pasching, Austria) supplemented with 10% fetal calf 
serum (FCS), 50 U/mL of penicillin and 500 µg/mL streptomycin without phenol red 
[21]. 1 ml Jurkat cell suspension (~2–3*105 cells/mL) per well was placed on a 24-
well plate and incubated with pure mTHPC (cmTHPC = 3 µmol/L), the polyelectrolyte 
(PSS Mw = 4.3 kDa with cPSS =  1.8 µmol/L) equal to the PSS concentration in the 
complex with cmTHPC = 3 µmol/L, and the complex at a concentration of 3 µmol/L 
mTHPC. The ethanol concentration in the cell suspension was 0.3% for better 
solubility of the pure drug. For this value no toxicity was observed. The incubation 
times were 1 h, 3 h, 5 h, and 24 h. 
For irradiation a laser diode with λem = 668 nm was used. The irradiation power was 
120 mW/cm2. The living and dead cell numbers were counted after additional 2 h 
incubation using a hemocytometer under an inverse microscope CKX 41 (Olympus, 
Hamburg). 
 
4.3 Results and Discussion 
4.3.1 PSS/mTHPP complexation efficiency 
First of all, an experiment has to be carried out to show that PSS can complex the 
drug mTHPP increasing the solubility in water. Therefore, different concentrated 
aqueous PSS (MWPSS = 4,300 g/mol) solutions were mixed with an ethanolic mTHPP 
solution of a fixed mTHPP concentration and freeze-dried. As expected, the higher 
the PSS concentration the higher was the mTHPP concentration determined in water 
(Figure 1). This effect could be explained by π-π interactions [22] between the PSS 
molecules with the mTHPP molecules which is an explicit hint for the successful 
complex formation of a water soluble complex. 
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mTHPC adsorbed  to PSS (MW = 4.3 
kDa) as function of PSS amount in 
water
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Figure 1: Solubility enhancement of mTHPP in water as function of PSS (4.3 kDa) 
amount added to 77 µg mTHPP, shown results after freeze drying and 
complex purification. 
 
The complexation efficiency of mTHPC with PSS is defined as the needful number of 
monomer units (4-ethyl(styrene sulfonate) sodium salt) (ESS, MW = 208 g/mol) to 
complex one mTHPP molecule. PSS with a molecular weight of 4,300 g/mol is 
composed of 21 EES units. The aim was to find the method and the conditions for 
the highest complexation efficiency between PSS and mTHPP, which was used as 
low cost drug alternative to mTHPC. 
For the determination of the complexation efficiency by UV/vis measurement the 
amount of substance ratio between both compounds was chosen to be 1:2.5 
(PSS:mTHPP). The excess of mTHPP compared to PSS was necessary to obtain a 
maximum complexation of mTHPP to PSS. To control the influence of the PSS 
molecular weight, different chain length of PSS (MW 0.21, 1.10, 1.92, 4.3, 13, 32.9, 
and 152 kDa) were complexed with the drug. With the monomer of PSS (MW 0.21 
kDa) it was not possible to form a complex with mTHPP. But with all other molecular 
weights of PSS (repeating units of PSS monomer: 5-740) a successful complex 
formation could be observed and the complexation efficiency was in each case 
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around 11±2 monomer units of PSS for the complexation of one mTHPP molecule 
(Figure 2). 
number of PSS monomer units for complexation of 1 mTHPC molecule
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Figure 2: Complexation efficiency of different PSS molecular weights with 
mTHPP. 
 
To find the highest complexation efficiency, several methods for complex formation 
were tested. For the evaporation of the mixture composed of ethanol/water (3:1 v/v), 
the complexation efficiency reached a value of 30 monomer units of PSS (Figure 3). 
Simple stirring of the aqueous suspension of PSS and mTHPP resulted in efficiency 
values dependent of the stirring time. The longer the stirring time the better was the 
complexation efficiency; after 12 days stirring at room temperature 142 monomers, 
after 22 days 67 monomers, and after 42 days 56 monomers of PSS were necessary 
to complex one mTHPP molecule (Figure 3). The best complexation efficiency with 
around 11 monomers was obtained by freeze-drying the ethanolic/aqueous mixture 
(1:1 v/v) followed by the evaporation method with 30 monomers but with the big 
disadvantage that it was necessary to evaporate the water. Therefore, a very careful 
handling and a long time interval for evaporation were essential. The stirring method 
was the most comfortable method but resulted in the worst complexation efficiency of 
56 monomers, in addition, after a very long time of 42 days. Interestingly, the freeze-
drying of both compounds only in water did not produce the complex because it 
seems to be essential that the drug is dissolved and homogeneously distributed with 
the polyelectrolyte during the freeze-drying process. 
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number of PSS (MW = 4.3 kDa) monomer units for complexation 
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Figure 3: Complexation efficiency by different methods of complex preparation 
between PSS (4.3 kDa) and mTHPP. 
 
Altogether the freeze-drying in an ethanolic/aqueous mixture was the most applicable 
procedure to complex the drug mTHPP to the polyelectrolyte PSS. The 4-
ethyl(styrene sulfonate) sodium salt (ESS) or the monomer of the PSS could not 
complex the drug. For all the other different molecular weights of PSS, between 
1.1 kDa and 152 kDa which is equal to 5 and 740 ESS units of the respective PSS 
the complexation efficiency resulted in 11±2 monomers of PSS to complex one 
mTHPP molecule. 
 
4.3.2 Preparation and characterization of PSS/mTHPC complex 
The mTHPP which is a model substance for mTHPC was used to find the general 
conditions for the complexation with PSS because it is much cheaper than the 
mTHPC. Nevertheless, the mTHPC is the approved drug showing the needed 
biological activity by the high intersystem crossing yield. To enable a renal clearance 
of PSS, a small molecular weight of 4.3 kDa for the PSS was chosen. That is why a 
preparation and characterization of a complex between PSS with a molecular weight 
of 4.3 kDa and mTHPC were carried out. 
To prepare the PSS/mTHPC complex, the freeze-drying method with the mixture of 
ethanol and water as the most efficient approach (determined with mTHPP) was 
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used. As expected only a part of mTHPC was complexed with PSS in water (pH 
value of 7.4) because the drug was used in excess compared to PSS to obtain a 
complete complexation of PSS. It seemed that more then half the mass of mTHPC 
could be not complexed with PSS because the mTHPC signal in ethanol has a higher 
absorbance compared to the mTHPC in water (Figure 4). However, the successful 
complex preparation was demonstrated by means of UV/vis measurement because 
the water solubility of mTHPC was dramatically increased. A further observation from 
the UV/vis spectra was the bathochromic shift (4-8 nm) of the absorption spectrum of 
mTHPC in water compared to that in ethanol which can be explained by the different 
polarity of the solvents (Figure 4). 
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Figure 4: UV/vis spectra of complexed mTHPC in water 1:100 dilution (black solid 
line), free or uncomplexed mTHPC in ethanol 1:100 dilution (black 
dashed line); both samples after freeze-drying, centrifugation, and 
filtration. 
 
As the activity depends also on the attachment of the drug to the PSS the aim was a 
non-covalent association of the drug to the polyelectrolyte (PE) PSS. Therefore, PSS 
was chosen because of its benzene rings in the molecule which can interact with the 
benzene rings in the mTHPC molecule [22]. To understand the interactions between 
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both molecules, molecular docking simulations were carried out. The first crude 
results were parallel displaced π-π interactions of benzene rings from PSS with the 
benzene- and pyrrole rings of mTHPC as well as H-bonds of OH- and NH-groups 
with the sulfonate groups (Figure 5) which lead to the successful complexation. 
4.5
4.0 3.0 
 
Figure 5: Docking complex between PSS (grey backbone) and mTHPC (cyan). 
The numbers indicate the distance between interacting groups in 
Angstrom. 
 
For the complex PSS/mTHPC the determination of the complexation efficiency was 
also investigated. To facilitate future quantification a calculation by CHNS elemental 
analysis was carried out and than compared with the results obtained by UV/vis 
analysis. The percentage of nitrogen in the PSS/mTHPC complex allowed 
quantifying the amount of mTHPC and the percentage of sulfur reflects the amount of 
PSS. The total mass of mTHPC in the complex based on the mass percentage of the 
elements in the complex was determined with 12.22 mg and the total mass of PSS 
with 47.84 mg (Table 1). Correspondingly, the mass percentage of mTHPC in the 
complex was 20.34% and 79.66% of PSS respectively. The complexation efficiency 
determined by elemental analysis resulted in a value of 13 ESS units for 
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complexation of one mTHPC molecule. Compared to the complexation of mTHPP 
with PSS, the complex efficiency was similar but slightly lower. To our speculation 
the reason for that could be the reduced aromatic characteristic of the one pyrrole 
ring due to the hydrogenation of one double bond in the pyrrole ring of the mTHPC 
molecule. Therefore, the interaction between the heterocyclic ring and the benzene 
rings of PSS molecule could be reduced, which results in a lower complexation 
efficiency. 
 
Table 1: Complex characteristics prepared with 50.14 mg PSS and 21.75 mg 
parameter for complex CHNS analysis UV/vis 
mTHPC by elemental analysis and UV/vis measurement (mean value ± 
standard deviation (SD)). 
total mass (mTHPC in complex) [mg] ± SD 12.22 ± 0.12 12.05 ± 0.36
total mass (PSS in complex) [mg] ± SD 47.84 ± 0.48 47.84 ± 0.48
20.34 ± 0.20 20.12 ± 0.60mass percentage (mTHPC) [%] ± SD 
79.66 ± 0.80 79.88 ± 2.40mass percentage (PSS) [%] ± SD 
number of monomers pro mTHPC molecule ± SD 12.93 ± 0.13 13.11 ± 0.39
 
 big advantage of the UV/vis measurement is the simple and cheap procedure A
being responsible for the omnipresence in research. The result 12.05 mg (Table 1) 
for the total mass of mTHPC in the complex determined by UV/vis analysis was 
obtained indirectly because mTHPC’s insolubility in water impeded a calibration in 
water. Furthermore, it was not possible by UV/vis measurement to determine the 
PSS concentration in the complex because of overlapping absorption of PSS and 
mTHPC. Therefore, the total mass of PSS in the complex obtained by elemental 
analysis was used for further calculations. The mass percentage of mTHPC in the 
complex was 20.12% and of PSS 79.88%, respectively, resulting in a complexation 
efficiency of 13 ESS units for the complexation of one mTHPC. Hence, both analysis 
resulted in the same complexation efficiency of 13 ESS units. However, the CHNS 
elemental analysis was the more precise method because of the direct determination 
of PSS and mTHPC in the aqueous phase. Therefore, the PSS loss of 5.4% during 
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the complexation and purification procedure could be detected. Without this 
information, the total PSS mass used in this experiment would be used for the 
calculation of complexation efficiency by UV/vis analysis because PSS is not soluble 
in ethanol resulting in around 14 EES units for complexation of one mTHPC 
molecule. Nevertheless, the UV/vis method is suitable for determination of the 
complexation efficiency. 
The challenge to prepare stable complexes with non-covalent attachment of the 
4.3.3 Singlet oxygen measurements 
antum yield is essential as this value is an 
4.3.4 Photodynamic activity and cytotoxicity 
n biological systems is the most 
water insoluble drug mTHPC to the water soluble polyelectrolyte PSS to transfer the 
drug in aqueous medium was successfully achieved. The stability of the complexes 
was tested and no modifications concerning color, haze or sedimentation could be 
found over a period of one year. Molecular docking simulations indicated interactions 
between both molecules due to the π-π interactions and H-bonds. To complex one 
mTHPC molecule, around 13 ESS units of one PSS chain (4.3 kDa) were needed 
even though no molecular weight dependence was observed for the drug analogue. 
 
The determination of the singlet oxygen qu
indication for the activity of the drug and hence, of the complex with PSS (4.3 kDa). 
As reference, Rose Bengal with a singlet quantum yield of 0.76 in D2O was used [23]. 
The singlet oxygen quantum yield of the PSS/mTHPC complex in D2O was 0.16 and 
0.31 of free mTHPC in ethanol. The 50% reduction of the singlet oxygen quantum 
yield of the complex compared to the free mTHPC could be also observed for other 
photosensitizer-carrier systems [24] and is probably caused by interactions between 
the mTHPC and the polymer. Hence, the higher solubility of the complex will 
overcome the lower quantum yield. 
 
Besides the production of singlet oxygen the activity i
relevant parameter for a potential application. Therefore, the phototoxicity of the 
complex to Jurkat cells was ascertained. Compared to the reference (untreated cells) 
the PE carrier PSS (4.3 kDa) alone did not induce toxic effects (Figure 6). This 
beneficial result allowed the usage of PSS as drug carrier system. The phototoxicity 
of the free mTHPC and the complexed mTHPC was equal with around 45% survival 
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rate after 3 hours. After 5 hours incubation time, the free mTHPC showed an 
increased phototoxicity of 62%. The complex did not show such an increase in 
phototoxicity remaining at the 3 hours incubation level. However, 24 h after irradiation 
the highest phototoxicity was induced by the complex (79% compared to the free 
mTHPC with only 69%). Apoptosis and necrosis could be observed both contributing 
to the overall toxicity. Further detailed analysis is ongoing to better understand the 
mechanism of the complex interaction. 
 
0
10
20
30
40
50
60
70
80
90
100
PSS (4300) reference mTHPC PSS
(4300)-
mTHPCsubstance
ce
ll 
co
un
t 
[%
]
1h 3h 5h 24h
 
Figure 6: Survival rate of Jurkat cells after 1, 3, 5, and 24 hours incubation time 
 
with 3 µM mTHPC and PSS/mTHPC complex followed by irradiation 
with white light: Light source: Exposure time: 1 min; Light dose: 
2 mJ/cm2. Error bars represent the standard deviation of nine 
measurements (n = 9). 
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4.4 Conclusion 
Poly(styrene sulfonate) sodium salt (PSS) is a non-toxic drug delivery system for 
Jurkat cells (clone E 6-1 human acute T-cell leukemia). The successful preparation of 
the water soluble and non-covalent linked PSS/mTHPC complex was achieved with a 
complexation efficiency of around 13 monomer units (4-ethyl(styrene sulfonate) 
sodium salt) of PSS, independent of the PSS molecular weight, to complex one 
mTHPC molecule. The freeze-drying method of an ethanolic/aqueous (1:1 v/v) 
mixture with both compounds resulted in the highest complexation efficiency 
compared to other techniques, like just stirring or evaporation. The complex showed 
a lower singlet oxygen quantum yield in water than the free mTHPC in ethanol. The 
improved water solubility allowed however, an improved phototoxicity. This non-toxic 
polyelectrolyte (PE) carrier in combination with its ability to improve the water 
solubility of the photosensitizer mTHPC showed a very promising phototoxicity. 
Hence, this simply prepared PSS/mTHPC complex facilitates a potential application 
in photodynamic therapy. However, the biochemical stability, the immune reaction to 
the polyelectrolyte, and in vivo PDT effects still need to be investigated. 
 
 
 
4.5 Supporting information 
 
Table S1: UV/vis calibration of mTHPP in ethanol 
Table S2: UV/vis calibration of mTHPC in ethanol 
 
 
 
Figure S1: CHNS elemental analysis of PSS (n=3) with set point as theoretical 
value and with measurement as measured value. 
Figure S2: CHNS elemental analysis mTHPC (n=3) with set point as theoretical 
value and with measurement as measured value. 
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Table S1: UV/vis calibration of mTHPP in ethanol 
λ [nm] A = ε*c*d, ε*d = x [µg/mL] Correlation 
factor  
Measurement range 
[µg/mL] 
416.0 0.83128 0.9999 0.01 -    1 
512.4 0.03019 0.9999 0.2   -  50 
546.0 0.01082 0.9999 1.0  - 100 
587.7 0.00871 0.9999 5.0  - 100 
644.5 0.00493 0.9999 10.0  - 100 
 
 
 
Table S2: UV/vis calibration of mTHPC in ethanol 
lambda [nm] A = ε*c*d, ε*d = x [µg/mL] correlation 
factor 
Measurement range 
[µg/mL] 
417 0.28301 0.9999 0.1 -     5 
517 0.06151 0.9999 2.0 -   50 
542 0.02341 0.9999 5.0  -   50 
597 0.01583 0.9999 10.0  - 100 
650 0.00886 0.9999 10.0  -   20 
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Figure S1: CHNS elemental analysis of PSS (n=3) with set point as theoretical 
value and with measurement as measured value. 
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Figure S2: CHNS elemental analysis of mTHPC (n=3) with set point as theoretical 
value and with measurement as measured value. 
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5 Chapter 3: Drug-multilayer coating of AuNP 
 
 
Multilayer coating of gold nanoparticles with drug-polymer 
coadsorbates* 
 
 
 
 
 
*This chapter has been published in: 
 
N. Reum, C. Fink-Straube, T. Klein, R. W. Hartmann, C. M. Lehr and M. Schneider. 
(2010) Multilayer coating of gold nanoparticles with drug-polymer coadsorbates. 
Langmuir, 26, 16901-16908. 
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Abstract 
The aim of our present study was the development of a drug multilayer-based carrier 
system for delivery of water-insoluble drugs. As drug, we applied the anticancer drug 
5,10,15,20-tetrakis(hydroxyphenyl)porphyrin, mTHPP which is a model 
photosensitizer for photodynamic therapy. Gold nanoparticles  with a diameter of 
14.5 ± 0.9 nm were prepared and used as template for the layer-by-layer approach. 
The drug and the negatively charged polyelectrolyte [1] poly(styrene sulfonate) 
sodium salt (PSS) were complexed with a new developed method using freeze-
drying. The complexation efficiency was determined to be ~11-12 monomers PSS 
per mTHPP molecule by CHNS analysis and UV/vis measurement. Molecular 
docking simulations revealed π-π interactions and H-bonding to be the responsible 
mechanisms. A drug multilayer system based on the layer-by-layer (LbL) technique 
utilized the water-soluble complex as anionic layer material and poly(allylamine 
hydrochloride) (PAH) as cationic layer. The modified AuNP were characterized by 
different physicochemical techniques such as UV/vis, ζ-potential, ICP-OES and TEM. 
To the best of our knowledge we could demonstrate for the first time the adsorption 
of three drug layers to a nanoparticulate system. Furthermore, the adaptation of the 
LbL-technique resulted in drastically increased drug deposition efficiency (factor of 
one 100). Furthermore, we developed a new and comfortable way to solubilize water-
insoluble drugs in water. 
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5.1 Introduction 
The photosensitizer mTHPP is a model anticancer drug best suited for mTHPC (tetra 
(hydroxyphenyl)chlorin) used as second-generation photosensitizer [2] in 
photodynamic therapy [3]. The drug is practically insoluble in water and must be 
intravenously administered, e.g., in ethanolic solution, causing local pain to patients 
[4]. Besides, the mTHPP molecules are only slowly released or degraded, because 
they tend to accumulate in the amphiphilic cell membrane[5]. As a huge 
disadvantage, the patients show a prolonged strong light sensitivity of up to two 
weeks after treatment due to the nonselective accumulation inside the tissue 
damaging both healthy and malignant cells by irradiation [4]. 
To overcome this obstacle, the usage of nanoparticles is a promising approach [6]. 
Chatterjee et al. divided the nanoparticle delivery systems for photodynamic therapy 
(PDT) in passive and active carriers for photosensitizer excitation [2]. Our focus is on 
passive carriers which are nonbiodegradable and metallic. Furthermore, the usage of 
such nanoparticles results in different advantages such as uptake into cells without 
being recognized by efflux systems (e.g., P-glycoprotein) resulting in the increased 
intracellular concentration of drugs [7]. A key advantage is the transport of 
hydrophobic drugs in the body, avoiding photosensitizer aggregation and inducing 
loss of activity. Additionally, they can show a minimum of immunogenicity and can 
also be designed to be resistant to microbial attack [2, 6]. The coating with 
poly(ethylene glycol) increases blood circulation time resulting in accumulation in 
cancer tissue by the so-called EPR effect [8, 9]. Hence, the intravenously 
administered drug delivery systems can increase the tumor concentration of 
antitumor drugs up to 70-fold [9, 10]. They can be synthesized in different sizes and 
can act as multifunctional platforms through (I) a shell volume in which 
photosensitizers can be encapsulated or coupled, (II) a surface that can be 
functionalized to attach targeting groups for cancer specific drug accumulation, and 
(III) a contrast agent that can be incorporated for diagnostic reasons [2, 6]. 
To ensure maximum flexibility for the drug carrier, modular systems are most suited. 
An intriguing approach is based on the layer-by-layer (LbL) technique introduced by 
Decher et al. [11] The LbL technique offers an endless variety of polyelectrolyte 
material and hence the preparation of tailor-made surfaces. Altough it was originally 
performed on planar surfaces, Sukhorukov et al. [1] transferred the LbL technique on 
microparticles by coating a template core. This template ascertains the size of the 
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particulate system, i.e., the drug carrier. Since then, a lot of work has been published 
mainly about microparticles and LbL self-assembly [12-15]. However, for cellular 
targeting and uptake nanosized particles are favorable. 
As a core material, colloidal gold was chosen because of its optical properties, the 
intriguing size range in which monodispers particles can be obtained, and its high 
chemical stability [16]. With respect to PDT, AuNP were also found to positively 
influence the singlet oxygen yield [17]. Furthermore, applying gold nanoparticles 
(AuNP) as a drug delivery system reduces and suppresses adverse effects due to 
particle toxicity. The usage of nanoparticles can also improve therapeutic efficiency 
and biodistribution, and overcomes the problems of solubility, stability, and 
pharmacokinetics of drugs [18, 19]. Furthermore, geometry and surface 
physicochemical properties affect the transport and biodistribution of particles at the 
vascular level and the strength of adhesion and the internalization rate at the cellular 
level [20]. The diameter and shape of AuNP can be easily diversified by application 
of different methods of AuNP preparation [21, 22]. Although the surface modification 
of AuNP was already carried out by Gittins and Caruso in 2000 [23], nanoparticles 
have up to now not been used intensively for coating by the LbL technique [24]. 
The kind of drug attachment to nanoparticles is constricted by the chemical structure 
of the drug molecule, the solubility, the stability, and the mechanism of action of drug, 
and furthermore dispersion medium, stability, size, and surface material of 
nanoparticles. To load the AuNP with drug, several methods have been published. 
Obvious is the attachment of siRNA and DNA as negatively charged polyelectrolytes 
by ionic interactions based on the LbL technique [25, 26]. Because of the structure of 
mTHPP, this principle is not available for mTHPP. Other possibilities for drug 
attachment to AuNP were carried out by coordinate-covalent bonding [27] and 
covalent bonding [28, 29]. The disadvantage for a covalent bonding of mTHPP can 
be the reduced drug efficiency through a lower singlet oxygen quantum yield.[2] Drug 
attachment by nitrogen-Au bonding systems [30] allows only one drug layer, reducing 
the dosing flexibility. Hence, a promising strategy for mTHPP attachment to AuNP 
surface is adsorption caused by interactions between the drug and the layer material 
as excipient. 
Our aim was the development of a nanoscale model for multilayer drug delivery 
system based on AuNP as templates allowing adjustment of the drug dose. The dose 
adjustment by varying the number of drug layers rather than the amount of particles 
 58 
  Chapter 3 
would improve the applicability. So far, most LbL systems in the nanorange are 
based on drug monolayers [24]. As layer material, we have applied two model 
polyelectrolytes for AuNP coating, PAH and PSS [31]. To avoid a strong reduction of 
the drug effect by covalent binding of mTHPP to AuNP surface, a coadsorbate of the 
water-insoluble mTHPP and the polyelectrolyte was formed by π-π interactions [32] 
and H-bonds resulting in a water-soluble polymer drug complex. The negatively 
charged complex consisting of PSS/mTHPP was applied as a layer material in 
combination with PAH (Scheme 1). Herein, for the first time AuNP coating is reported 
with several (three) drug layers to obtain a real multilayer drug delivery system. 
 
 
Scheme 1:  Principle of mTHPP loaded AuNP manufacture using standard LbL 
method. 
 
5.2 Materials and methods 
5.2.1 Materials 
The 5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrin (mTHPP) seen in Scheme 1 was 
kindly provided by Biolitec AG (Jena, Germany). Gold(III) chloride hydrate 
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(HAuCl4·3H2O), trisodium citrate-2-hydrate (Na3C6H5O7·2H2O), poly(styrene 
sulfonate) sodium salt (PSS) (MW 4.3 kDa), and poly(allylamine hydrochloride) 
(PAH) (MW 15.0 kDa) were purchased from Sigma-Aldrich (Steinheim, Germany). 
The water used in all experiments was prepared in a Millipore Milli-Q purification 
system (resistivity higher than 18.0 MΩ cm-1). 
 
5.2.2 Methods 
5.2.2.1 Preparation of PSS/mTHPP complex 
86.0 mg (20.0 µmol) of PSS was dissolved in 15 mL water. 27.0 mg (39.7 µmol) of 
mTHPP was dissolved in 15 mL ethanol. Both solutions were mixed and freeze-dried 
in a Christ Alpha 2-4 LSC (Christ GmbH, Osterode, Germany). The lyophilizate was 
suspended in 20 mL of water and centrifuged for 35 min at 16,098 g with a table 
centrifuge, Hettich Rotina 420 R (Hettich GmbH & Co. KG, Tuttlingen, Germany). 
The supernatant was filtered and refilled with water to 25 mL. The pellet of 
centrifugation, the filters, and all other materials that were in contact with the complex 
mixture were rinsed out with ethanol, which was collected to determine the 
concentration of free or uncomplexed mTHPP. The concentration of mTHPP in 
ethanol was obtained by UV/vis spectroscopy (5 relevant peaks: λex ∈ {416, 512, 
546, 589, 645} nm) (PerkinElmer Lambda 35, PerkinElmer LAS, Rodgau, Germany) 
and the concentration of PSS and mTHPP in water by CHNS analysis (Elementar 
Analysensysteme GmbH, Hanau, Germany). 
 
5.2.2.2 Characterization of PSS/mTHPP coadsorbate 
5.2.2.2.1 Docking study 
Molecular docking simulations were carried out to simulate, predict, and better 
understand the interactions between the drug (mTHPP) and the polyelectrolyte 
carrier (PSS). All calculations were performed on Intel Core2 Duo CPU 3.00 GHz 
running Linux CentOS 5.3. Tridimensional structures of both mTHPP and PSS were 
generated using MOE2008.10 (Chemical Computing Group Inc., Montreal, Canada). 
For simplification, the PSS molecule was depicted as a nine monomer unit. The 
structures were energy-minimized with the MMFF94 force field as implemented in 
MOE. Ionization states and hydrogen positions were assigned using the Protonate 
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3D utility of MOE. AutoDock-Tools4 [33] was used for input files preparation and 
AutoDock Vina, version 1.0 [34] was used to dock mTHPP in the structure of PSS: 60 
binding modes were produced with an exhaustiveness parameter of 100. 
 
5.2.2.2.2 CHNS elemental analysis 
The determination of CHNS contents of drug complexes was carried out by universal 
elemental analyzer vario El III (Elementar Analysensysteme GmbH, Hanau, 
Germany). The basic principle of quantitative CHNS analysis is high-temperature 
combustion of organic solid or liquid samples. Programmable control of the direct 
oxygen jet injection during high-temperature combustion guarantees complete 
combustion. The gaseous combustion products are purified, separated into their 
components by special adsorption traps, and sequentially analyzed with universally 
used thermoconductivity detector (TCD). 
Samples were weighed into tin boats, compressed, and taken to the auto sampler, 
where they are dropped into the combustion tube automatically. Calibration curves of 
sulfanilic acid as reference compound (,: 41.6; H, 4.1; N, 8.1; and S, 18.5 wt %) were 
compiled by manufacturer, and daytime factor measurements were repeated six 
times with weighed samples of about 5 mg. The aqueous solution of PSS/mTHPP 
complex was freeze-dried with Christ Alpha 2-4 LSC (Christ GmbH, Osterode, 
Germany). Freeze-dried drug polymer coadsorbate analysis was repeated three 
times with weighed samples of about 3 mg. The temperatures of combustion tube, 
reduction tube, CO2 column, H2O column, and SO2 column amounted to 1150, 850, 
190, 150, and 210°C, respectively. 
 
5.2.2.2.3 UV-visible spectroscopy measurements 
The amount of mTHPP in the drug complex was determined indirectly based on 
UV/vis spectroscopy. Therefore, the concentration of mTHPP in the organic solution 
(ethanol) was calculated (see Results and Discussion). All measurements were 
carried out in 1 cm quartz cuvettes with the Perkin-Elmer Lambda 35 
spectrophotometer (PerkinElmer LAS, Rodgau, Germany). 
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5.2.2.3 Synthesis of AuNP 
Colloidal gold was prepared following a method introduced by Turkevich et al. [35] by 
the reduction of gold ions with citrate ions [36]. A volume of 99 mL of a tetrachlorauric 
acid (HAuCl4·3H2O) solution containing 20 mg (50.8 µmol) of gold salt were refluxed 
and 1 mL of sodium citrate solution containing 74.7 mg (254 µmol) of 
Na3C6H5O7·2H2O was added to the boiling solution. The solution was boiled for 20 
min and cooled to room temperature. The resulting suspension had a gold 
concentration of 100 µg/mL analyzed by ICP OES. 
 
5.2.2.4 Preparation of PAH and PSS/mTHPP coated AuNP 
5.2.2.4.1 Standard LbL method 
For encapsulation of colloidal gold nanoparticles, we used an adapted method 
formerly described by Decher [31] and Krol [37] using PAH and drug polymer 
complex instead of pure polymers. To 10 mL of unwashed-citrate-stabilized gold 
nanoparticle solution with a gold concentration of 100 µg/mL was added 10 mL of the 
PAH solution (10 mg/mL) resulting in 110,000 PAH chains per AuNP determined 
following Schneider et al. [38]. After stirring for 10 min, particles were separated from 
PAH excess by centrifugation at 23,143 g for 35 min (Hettich Rotina 420 R, Hettich 
GmbH & Co. KG, Tuttlingen, Germany). The centrifuged nanoparticles were 
redispersed in water to a volume of 10 mL. The washing step was repeated once. 
Ten milliliters of PAH-coated AuNP was coated with 10 mL of the drug complex 
solution. The drug complex was applied in water with a concentration of 111 µg/mL 
PSS and 32 µg/mL mTHPP, respectively. That means per AuNP are available 4,200 
PSS chains. The quantification of mTHPP/PSS complex will be described in the 
results and discussion section. After incubation for 10 min, the solution was 
centrifuged for 35 min at 14,800 g with a table centrifuge. The supernatant was 
removed and replaced by the necessary volume of water to obtain 10 mL of AuNP 
coated with PAH and PSS/mTHPP (AuNP(PAH/PSS+mTHPP)1). Then, the next PE 
double layer was deposited, repeating the procedure. 
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5.2.2.4.2 Modified LbL method 
Modified LbL was similar to the standard method, but instead of twice-washed 
AuNP(PAH), only once-washed AuNP(PAH) were used. The drug complex was 
applied in water at a concentration of 100 µg/mL PSS and 29 µg/mL mTHPP (per 
AuNP are 3,784 PSS chains available), respectively. Afterwards, a third layer of pure 
PSS was used again with a concentration of 3.5 mg/mL. To 10 mL of 
AuNP(PAH/PSS+mTHPP)1 was added 10 mL of PSS solution (per AuNP are 
450,000 PSS chains available). The modified AuNP were washed twice, and then, 
PAH was adsorbed as the fourth layer as described before. 
 
5.2.2.5 Characterization of AuNP and coated AuNP 
5.2.2.5.1 Transmission electron microscopy (TEM) measurements 
TEM measurements of the gold nanoparticles were performed on a JOEL model JEM 
2010 instrument (JOEL GmbH, Eching, Germany) operated at an accelerating 
voltage of 120 kV. Samples for TEM analysis were prepared by placing 12 µL of 
washed gold nanoparticle solution on carbon-coated 400 mesh copper grid (S160-4, 
Plano GmbH, Wetzlar, Germany). The suspensions were allowed to dry until the 
water was completely evaporated. Contrast agent was not applied. 
 
5.2.2.5.2 Particle size analysis 
The particle size analysis of TEM images was carried out of around 100 particles 
using ImageJ. The real median diameter was determined. 
 
5.2.2.5.3 Atomic emission spectrometry with induced coupled plasma (ICP OES) 
Atomic emission spectrometry with induced coupled plasma (ICP OES) was 
performed using an Ultima 2 (Horiba Jobin-Yvon, Longjumenau, France) with a 
Czerny-Turner type monochromator (focal length 1 m). HF power of 1 kW was 
supplied by a regulated generator at 40.68 MHz. The liquid sample is nebulized, then 
transferred to argon plasma. It is decomposed, atomized, and ionized whereby the 
atoms and ions are excited. The intensity of light emitted is measured when the 
atoms or ions return to a lower energy. Each element emits light at characteristic 
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wavelengths, and these lines can be used for quantitative analysis (Supporting 
Information Table S1). 
Standard solutions were prepared from single-element stock solutions (1.000 g/L) 
obtained from Alfa Aesar GmbH and Co KG (Karlsruhe, Germany). Ultrapure water 
was used for dilution of standards. Calibration was performed using aqueous 
standard solutions of 0, 5, and 10 mg/L and led to calibration coefficients of 0.999 in 
the case of Au. In contrast to the typical procedure, we have not dissolved the AuNP 
in aqua regia but the colloidal Au solutions were diluted 1:10 with ultrapure water for 
analysis. All measurements were done in triplicate. 
 
5.2.2.5.4 ζ-potential measurements 
The ζ-potential of uncoated, coated, and mTHPP-loaded AuNP was determined by 
the principle of laser Doppler velocimetry with a Malvern Zetasizer Nano ZS (Malvern 
Instruments GmbH, Herrenberg, Germany). Measurements were realized in triplicate 
at 25 °C with the model of Smoluchowski. 
 
5.2.2.5.5 UV-visible spectroscopy measurements 
UV/vis spectroscopy was carried out to check the successful polyelectrolyte and drug 
adsorption to AuNP surface. Furthermore, the adsorbed mTHPP mass to AuNP 
surfaces was determined. All measurements were carried out in 1 cm quartz cuvettes 
with the Perkin-Elmer Lambda 35 Spectrophotometer (PerkinElmer LAS, Rodgau, 
Germany). 
 
5.3 Results and discussion 
5.3.1 Preparation of PSS/mTHPP complex 
The aim was the noncovalent attachment of drug to the polyelectrolyte (PE) PSS. 
The advantage of drug adsorption to PSS is the direct coating of AuNP with the 
PSS/mTHPP complex. PSS was chosen because of its benzene rings in the 
molecule which can interact with the benzene rings in the mTHPP molecule. The 
water solubility of mTHPP coadsorbed with PSS is remarkably enhanced, which is a 
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clear hint for successful complex formation between both compounds (Supporting 
Information Figure S1). 
To understand the interactions between both molecules, a molecular docking 
simulation was carried out. The first crude results were parallel displaced π-π 
interactions of benzene rings from PSS with the benzene and pyrrole rings of 
mTHPP as well as H-bonds of OH- and NH-groups with the sulfonate groups 
(Supporting Information Figure S2) which lead to the successful complexation. The 
π-π interactions also resulted in a red shift of the mTHPP absorption spectrum of the 
complex in water, as expected (Figure 1). 
An intriguing aspect is the complexation ratio between the drug and the PSS 
molecules. CHNS elemental analysis was carried out to determine the mass fraction 
of both compounds in the complex. The results of CHNS elemental analysis of PSS 
and mTHPP in mass percentage C, H, N, and S were found to yield a very small 
standard deviation (Supporting Information Figure S3). The recovery rate of PSS 
relating to carbon and sulfur is only 86% because of the impurities (unspecified by 
producer) reducing the actual content of PSS [39]. The recovery rate of mTHPP 
relating to carbon and hydrogen is 97%, for nitrogen, it is 91%. For determination of 
complexation ratio, the recovery rate of PSS and mTHPP has to be considered. 
To determine the mTHPP concentration in the complex in water, a fixed volume of 
10 mL of the aqueous complex solution was freeze-dried and analyzed by elemental 
analysis. On the basis of the mass percentage of the elements in the complex 
(Supporting Information Table S2), the amount of complex in the aqueous phase was 
105.7 mg, indicating that 6.5% of the PSS/mTHPP coadsorbate is transferred into the 
ethanolic phase (total mass = 86 mg PSS and 27 mg mTHPP = 113 mg). This result 
fits the visual observations clearly including mTHPP in ethanol due to the red/brown 
discoloration of ethanol after contact with the PSS/mTHPP mixture. In the aqueous 
phase, 77.85% PSS and 22.78% mTHPP were determined with an excellent rate of 
recovery (Supporting Information Table S2). One PSS molecule (~ 4,300 g/mol) 
consists of around 21 monomer units (206.18 g/mol). Therefore, the result of 
complexation efficiency of 11 monomers units of PSS per mTHPP molecule or 2 
mTHPP molecules per PSS molecule is very reliable (Table 1). 
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Table 1: Complex characteristics prepared from 86 mg PSS and 27 mg mTHPP 
by elemental analysis and UV/vis measurement (mean value ± standard 
deviation (SD)). 
parameter for complex CHNS analysis UV/vis 
m(free mTHPP in ethanol) [mg] ± SD 2.92 ± 0.180 2.95 ± 0.330
m(mTHPP in complex in water) [mg] ± SD 24.08 ± 0.180 24.05 ± 0.330
m(PSS in complex) [mg] ± SD 82.29 ± 1.069 86.00 ± 0.000
m(complex) [mg] ± SD 106.37 ± 1.181 110.05± 0.330
number of monomers per mTHPP molecule ± SD 11.25 ± 0.062 11.80 ± 0.039
 
To facilitate the determination of the complexation ratio, an approach based on 
UV/vis was investigated. The determination of complex concentration by UV/vis 
spectroscopy would offer a simple and cheap method to be carried out in all 
laboratories. A disadvantage of UV/vis measurement is that the calibration of mTHPP 
is not possible in the aqueous phase, because the drug is practically insoluble in 
water (a UV/vis calibration in water cannot be performed). Due to complex 
preparation and purification, the free mTHPP is dissolved in ethanol, whereas free 
PSS is insoluble in ethanol. However, an indirect determination of mTHPP 
concentration in water can be carried out in ethanol. As the PSS/mTHPP complex is 
insoluble in ethanol, only the unbound mTHPP can be in the ethanol phase. The 
concentration of complexed mTHPP in water (c(mTHPP)) can be determined with 
equation (1) with m(total) as the total mass of mTHPP for complex preparation, m(ethanol) 
as the free or uncomplexed mTHPP mass in ethanol determined by UV/vis 
measurement, and V as the volume of water with the PSS/mTHPP coadsorbate: 
V
mm
c ethanoltotalmTHPP
)()(
)(
−=    (1) 
Drug mass in water or complexed mTHPP mass is the mass of mTHPP used for 
complexation minus mass of mTHPP in ethanol assuming that there is no loss of 
mTHPP during the complexation procedure. The UV/vis spectrum of mTHPP in 
ethanol indicates five peaks as seen in Figure 1. For all calibration curves was 
obtained a very high linearity of around 0.9999. Samples can be measured in a broad 
range between 10 ng/mL and 100 µg/mL due to selection of different measurement 
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wavelengths. In Table 1, one can find the total mass of free or uncomplexed mTHPP 
in ethanol, which is 2.95 mg. That means 24.05 mg of the used drug mass was 
complexed by 86 mg PSS (Table 1). With the help of the knowledge about the mass 
of mTHPP and PSS in the complex solution, a complexation efficiency of twelve 
monomer units of PSS for one mTHPP molecule was calculated based on UV/vis 
spectroscopy. 
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Figure 1: UV/vis spectra of complexed mTHPP in water 1:100 dilution (black solid 
line), free or uncomplexed mTHPP in ethanol 1:100 dilution (black 
dashed line) – both samples after freeze-drying, centrifugation, and 
filtration; 2 µg/mL mTHPP in ethanol (gray solid line) and PSS 
c(PSS) = 17 µg/mL (gray dashed line) in water. 
The total volume of the aqueous complex solution was 25 mL and the pH value was 
7.4. The total volume of the free, uncomplexed mTHPP was also 25 mL but with 
ethanol as solvent. In Figure 1, one can see the absorption of 1:100 diluted 
PSS/mTHPP complex in water (black solid line) and of 1:100 diluted free mTHPP in 
ethanol (black dashed line). As a comparison to the free mTHPP of the complexation 
procedure, the solid gray line indicates mTHPP concentration of 2.0 µg/mL in ethanol 
(Figure 1). The adsorption spectra allowed identification of the drug. PSS with a 
concentration of 17 µg/mL in water (gray dashed line) is characterized by a peak 
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near 225 nm as shown in Figure 1. This peak can only be found in the water phase, 
whereas PSS was not detected in the organic phase (PSS not soluble in ethanol). 
Comparing the results of the elemental analysis with those of the UV/vis 
measurements indicates the similar complexation efficiencies between PSS and 
mTHPP (Table 1). The mTHPP mass was the same for both measurements 
(mTHPP= 24.1 mg). PSS could only be detected by elemental analysis (82.29 mg 
indicating a loss of 3.71 mg or 4.3%) because of the overlapping UV/vis signal of 
PSS and mTHPP at λ = 225 nm. As PSS is not soluble in ethanol, all PSS 
(mPSS= 86 mg) is assumed to be in the aqueous phase. The results of elemental 
analysis indicate differences most likely due to the adsorption of PSS to the 
membrane material of the filters or to the surface of the equipment. With elemental 
analysis, a value of 11.3 monomer units (4-ethylbenzenesulfonate sodium salt, 
206.2 g/mol) of PSS (4,300 g/mol) was calculated to complex 1 mTHPP molecule 
and by UV/vis measurement, it was 11.8 monomer units of PSS. The fewer monomer 
units necessary to complex 1 mTHPP molecule, the better the complexation 
efficiency is. The more precise method from the direct determination of PSS and 
mTHPP in aqueous phase (elemental analysis) leads to higher complexation 
efficiency than the UV/vis method. Nevertheless, the UV/vis method is suitable for 
determination of complexation efficiency. To test the complexation efficiency, the 
mass ratio between mTHPP and PSS was changed. However, 11 monomer units of 
PSS for 1 mTHPP molecule was the most effective result relating to the highest 
complexation efficiency. 
The stability of such complexes was also checked, and no modifications concerning 
color, haze, or sedimentation could be found over a period of one year. The idea to 
form stable complexes of the water-soluble polymer PSS with the water-insoluble 
drug mTHPP to transfer the drug in aqueous medium was successfully achieved. 
Molecular docking simulations could indicate interactions between both molecules 
due to the π-π interactions and H-bonds. For complexation of 1 mTHPP molecule, 
around 11 monomers of the PSS chain were needed. 
 
5.3.2 Synthesis of gold nanoparticles (AuNP) 
Colloidal gold prepared from trisodium citrate-2-hydrate was characterized by TEM 
and showed a monodisperse size distribution with a median particle diameter of 
14.5 nm and a standard deviation of 0.9 nm (Figure 2). As expected, the ζ-potential 
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of citrate stabilized AuNP has shown a negative value because of the citrate ions on 
the surface of AuNP [38]. With the help of the equation (2) from Haiss et al. [40] and 
the UV/vis data, we could also calculate the AuNP diameter, obtaining a value of 
(14.1 ± 0.8) nm which is equal to the result by TEM measurement. 
( )
( )
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     (2) 
With d the diameter of the particles in nanometer (for 5 nm ≤ d ≤ 30 nm), cAu the gold 
concentration (mol/L), ASPR the absorbance at the surface plasmon resonance of 
AuNP solution, and C1 = -4.75, C2 = 0.314 being specific constants. 
The concentration of gold in the freshly prepared AuNP suspension was determined 
by ICP-OES. In comparison to the typically described procedure in literature [41], it 
was not necessary to dissolve the AuNP in aqua regia before ICP-OES 
measurement. A 100% transformation of gold cations to AuNP could be observed, as 
UV/vis measurement indicated no gold salt after redox reaction. In combination with 
the ICP-OES results, the number of waters of crystallization in the tetrachlorauric 
acid compound was determined to be 3. 
 
Figure 2: A) TEM image of citrate-stabilized AuNP. B) Size distribution of citrate-
stabilized AuNP (analysis of the TEM image with Image J software). 
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5.3.3 Preparation of PAH and PSS/mTHPP coated AuNP 
5.3.3.1 Standard LbL method 
Scheme 1 depicts the principle of mTHPP loaded AuNP preparation with the layer-
by-layer deposition technique. As first layer, PAH was adsorbed; therefore, the ζ-
potential changed from negative values with citrate-stabilized AuNP to positive 
charges (Supporting Information Table S4) [38]. In Figure 3 is shown the typical 
absorption spectrum of citrate-stabilized AuNP (black solid line) and AuNP(PAH) 
(black dashed line). The peak near 520 nm is caused by surface plasmon resonance 
(SPR) of AuNP [19]. The adsorption of PAH leads to a little red shift of the AuNP 
peak of 1 – 2 nm due to interactions of electrons from the surface of AuNP with the 
adsorbed polyelectrolyte PAH and a broadening of the peak on the right side (black 
dashed line in Figure 3). Via washing steps, the excess PAH was removed resulting 
in the pH increase of the colloidal solution from 3.7 to 4.9. 
 
Figure 3: UV/vis spectra with ABC between 338 and 519 nm of the standard LbL 
method from AuNP-citrate to AuNP (PAH/ PSS+mTHPP)2PAH: black 
solid line = layer 0 ≙ unwashed citrate-stabilized AuNP; black dashed 
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line = layer 1 ≙ twice-washed AuNP with PAH as first layer; gray solid 
line = layer 3 ≙ twice-washed AuNP with PAH as first layer, 
PSS/mTHPP complex as second layer, and PAH as third and last layer 
(AuNP(PAH/PSS+mTHPP/PAH)1; gray dotted line = layer 5 ≙ twice-
washed AuNP with PAH as first layer, PSS/mTHPP complex as second 
layer, PAH as third layer, PSS/mTHPP complex as fourth layer, and 
PAH as fifth and last layer AuNP(PAH/PSS+mTHPP)2PAH. 
 
The complex composed of PSS and mTHPP was adsorbed as second layer. 
Schneider et al. [38] identified that 60,000 PE chains per AuNP resulted in the 
highest single, non-aggregated AuNP yield. Here, however, only 4,200 PSS chains 
were available per AuNP. The idea behind this was to reduce the excess material 
and to increase deposition efficiency. Both procedures resulted in the same drug 
loading onto the AuNP, hence increasing the loading efficiency. Adsorbing the 
polyelectrolyte drug coadsorbate changed the ζ-potential to a negative value. As third 
layer, we have deposited PAH again, reversing the ζ-potential to positive values. The 
absorption spectrum of twice-washed AuNP(PAH/PSS+mTHPP/PAH)1 is also 
presented in Figure 3. We could observe again a small red shift of AuNP peak of 2 - 
3 nm due to the two further layers in comparison to AuNP(PAH)1. More interestingly, 
the spectrum indicates an additional peak near 420 nm originating from mTHPP 
deposited as a complex on the AuNP surface. 
Furthermore, adjusting the dose would require tuning the drug amount on the carrier. 
Therefore, additional layers were added. The absorption spectrum was always 
recorded after two washing steps. Whereas the AuNP peak was altered only 
marginally (Figure 3), the peak of mTHPP increased considerably, and that is a 
cogent hint for a second mTHPP layer adsorbed onto AuNP surface. The colloidal 
solutions of AuNP(PAH/PSS+mTHPP)2PAH have not indicated agglomerated AuNP 
being stable for at least three months. The flocculation level, a stability parameter 
introduced by Weisbecker et al. [42], did not show differences between the citrate-
stabilized AuNP and the coated AuNP. The calculation of the area between the 
curves (ABC) between 338 nm and 519 nm of AuNP(PAH)1, 
AuNP(PAH/PSS+mTHPP/PAH)1, and AuNP(PAH/PSS+mTHPP)2PAH (Figure 3) 
allows determination of the increase of mTHPP molecules adsorbed onto the AuNP 
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surface. The ABC of AuNP with the first mTHPP layer is defined as 100% value 
(Figure 3). After adsorbing the second mTHPP layer, one could expect to slightly 
exceed doubling the ABC (ABCmTHPP-2 ≙ 222%). The reason for that might be the 
longer perimeter due to two further polyelectrolyte layers (+21% assuming a layer 
thickness of 0.8 nm). With our experimental data, we could show for the first time the 
preparation of AuNP surfaces modified by the so-called LbL technique with repetitive 
drug layers due to complex formation between the water-insoluble mTHPP and the 
negatively charged polyelectrolyte PSS. 
So far, it was possible to transfer the water-insoluble drug due to complexation with 
PSS into aqueous solution. The deposition of the complex onto the surface of 
AuNP(PAH) via layer-by-layer technology could also be successfully achieved. That 
means we can apply the drug polymer coadsorbate of PSS and mTHPP like PSS 
alone regarding the layer-by layer technique. Zhifei Dai et al. published in 2001 the 
incorporation of dyes into layers of microparticles but due to ionic interactions of dyes 
and polyelectrolytes [43]. The formation of such a polymer drug complex is a new 
and comfortable method for drug incorporation into the layers, which is even working 
for coatings of nanoparticles. 
 
5.3.3.2 Modified LbL method 
To reduce the number of aggregated AuNP during the LbL coating, a modified LbL 
procedure was developed. Therefore, once- and twice-washed AuNP(PAH)- and 
different complex concentrations were mixed together. After centrifugation of the 
mixture, the yield of AuNP was determined by UV/vis. Surprisingly, the highest yield 
(92%) was obtained with once-washed AuNP(PAH) solution with a gold 
concentration of 50 µg/mL and with a PSS concentration of 50 µg/mL, which 
corresponds to 3,784 PSS molecules for 1 AuNP. 
The ζ-potential changed from +62 mV with (AuNP(PAH)) to +50 mV with 
(AuNP(PAH/PSS+mTHPP)) (Figure 4) in contrast to the standard method. The 
reason for the incomplete charge reversal could be either a lower amount of 
adsorbed drug complex or a complex formed between the mTHPP/PSS coadsorbate 
and unbound PAH in solution. In either case, as a consequence the AuNP surface 
has to be modified with additional PSS for charge reversal of the coated AuNP before 
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adsorption of the successive PAH layer is possible. PSS coating resulted in a ζ-
potential of -54 mV. 
In Figure 4 are depicted the ζ-potentials and pH values during the coating procedure. 
Both values are very important for cell experiments or nanoparticle stability in a 
medium requiring enough stability at physiological pH. PAH is a weak PE with a 
strong chloride anion as counterion, and that is why the pH values are low, ca. 3.8 
after addition of PAH. PSS is a strong PE with a strong sodium cation as counter-ion, 
and after addition of PSS to modified AuNP solution, the pH values are between 6 
and 7. AuNP with PAH as the outer layer indicate a positive ζ-potential, while with 
PSS as the outermost layer a negative ζ-potential was obtained. AuNP with drug 
complex as the outer layer always showed only a decrease of ζ-potentials from 
60 mV to 40 mV as described above for the first adsorbed layer. 
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Figure 4: Changes of pH value and ζ-potential of surface-modified AuNP by 
modified LbL method (unwashed, *once washed, **twice washed). 
 
UV/vis spectra indicate definitely that three complex layers could be adsorbed to the 
AuNP surface using the LbL technique (Figure 5). Spectra of AuNP, AuNP(PAH), 
and AuNP with one complex layer are described in section 3.3.1. In comparison to 
the mTHPP peak near 420 nm of the standard method (Figure 3) the mTHPP peak of 
AuNP with one drug layer in Figure 5 was narrower in width and therefore higher. 
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The peak of 225 nm caused by PSS was clearly higher in Figure 5 than in Figure 3. 
That is an indication for a higher concentration of PSS adsorbed to AuNP in the 
modified method because of the additional PSS layer compared to the standard 
method. The increase of the mTHPP peak with the second drug layer was smaller in 
the modified procedure than in the standard procedure. The third drug layer caused a 
similar increase as the second adsorbed mTHPP layer (increase of ABC of 70%). 
 
From AuNP-citrate to 
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Figure 5: UV/vis spectra of modified LbL method from AuNP-citrate to 
AuNP(PAH/PSS+mTHPP/PSS)3PAH: black solid line = layer 0 ≙ 
unwashed citrate-stabilized AuNP; black dashed line = layer 1 ≙ twice-
washed AuNP with PAH as first layer; gray solid line = layer 4 ≙ twice-
washed AuNP with PAH as first layer, PSS/mTHPP complex as second 
layer, PSS as third layer, and PAH as fourth and last layer 
(AuNP(PAH/PSS+mTHPP/PSS/PAH)1; gray dotted line =l ayer 7 ≙ 
twice-washed AuNP with PAH as first layer, PSS/mTHPP complex as 
second layer, PSS as third  layer, PAH as fourth layer, PSS/mTHPP 
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complex as fifth layer, PSS as sixth layer, and PAH as seventh and last 
layer (AuNP(PAH/PSS+mTHPP/ PSS)2PAH)1; black spotted line = layer 
10 ≙ twice-washed AuNP with PAH as first layer, PSS/mTHPP complex 
as second layer, PSS as third layer, PAH as fourth layer, PSS/mTHPP 
complex as fifth layer, PSS as sixth layer, PAH as seventh layer, 
PSS/mTHPP complex as eighth layer, PSS as ninth layer, and PAH as 
tenth and outer layer material (AuNP(PAH/PSS+mTHPP/PSS)3PAH)1. 
To determine more precisely the number of adsorbed mTHPP molecules to AuNP 
surface, the ABC were calculated as before. ABC of one drug layer with standard 
method was 25 nm (Figure 3) and with modified method 24 nm (Figure 5). This is a 
clear hint that all uncomplexed mTHPP molecules were removed completely by 
washing steps. Complex layer two caused an increase of the ABC to 40 nm, and that 
corresponds to an increase of ABC of only 168%. The ABC of AuNP with three 
complex layers was 58 nm or 244% (Figure 5) compared to the first drug layer with 
24 nm or 100% (Figure 5). That means the total increase of ABC with three mTHPP 
layers was a little bit higher than the increase of ABC with two drug layers. However, 
compared to the standard method the AuNP loss during the washing steps was 
reduced by this modified procedure. Therefore, it was possible to enhance the 
number of drug layers adsorbed to the AuNP surface. 
As the overall amount of material on the particles is of interest, the number of 
adsorbed PSS molecules onto the AuNP was estimated by two approaches: the 
projected surface area of 1) a PSS random coil (Mw = 4,300 g/mol; r = 0.573 nm) 
A(rc) = 1.03 nm² and of 2) a stretched PSS molecule (cylinder geometry) 
A(cg) = 4.03 nm² was calculated. Together with the available surface area of the AuNP 
(d = 14.5 nm; c(AuNP) = 50 µg/mL, PAH layer of 0.4 nm thickness determined by TEM) 
8 µg/mL random coiled PSS or 2 µg/mL stretched PSS molecules would be 
necessary for complete coverage of the available AuNP surface. From the 
complexation efficiency, the adsorbed amount of mTHPP was found to be 
2.28 µg/mL for random coiled PSS or 0.57 µg/mL for stretched PSS. 
Analyzing the AUC(338-519 nm) of the mTHPP peak furthermore allowed a determination 
based on the experimental results. Therefore, the AUC(338-519 nm) of free mTHPP in 
ethanol was assumed to be equal to the ABC(338-519 nm) of mTHPP adsorbed to AuNP 
in water resulting in equal mTHPP concentrations. The AUC(338-519 nm) of mTHPP 
correlated linearly with the concentration of mTHPP in ethanol solution. Calculated 
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results of ABC (Table 2) are in the same range as the values determined over the 
surface area. With around 2.1 µg/mL mTHPP adsorbed to AuNP surface for the first 
drug layer (is equal to 1035 mTHPP molecules to 1 gold nanoparticle with a diameter 
of 14.5 nm), the concentration is close to the calculated value with the random coiled 
PSS molecule structure, which was 2.28 µg/mL. Therefore, it seems that most of the 
PSS molecules are adsorbed in a random coiled structure. Because of the strong 
polyelectrolyte characteristic of PSS, a more stretched structure was expected. 
However, the previously mentioned complex formation of coadsorbate and unbound 
PAH would lead to a lower charged complex with a nonstretched architecture 
supporting the estimation based on a random coil. With three complex layers of 
modified LbL procedure, the mTHPP concentration adsorbed to the AuNP surface 
was increased to 4.8 µg/mL. In this study, the drug mTHPP is applied as a model 
drug for the active pharmaceutical ingredient mTHPC (meta-
tetra(hydroxyphenyl)chlorin). Typical tissue concentrations tested on several 
carcinoma cell lines for efficient tumor treatment with mTHPC are around 1.0 µg/mL 
indicating that the concentration on the particles would be high enough for application 
[44-46]. To summarize, the quantification of mTHPP adsorbed to AuNP based on 
UV/vis spectroscopy was well in accordance with the theoretical estimation of the 
adsorbed drug amount. Furthermore, the model used for estimation allowed us to 
conclude that the polymer seems to be adsorbed mainly as PAH-coadsorbate 
complex. 
Table 2: Quantification by UV/vis spectroscopy of mTHPP adsorbed to AuNP 
surface with c(Au) = 50 µg/mL and AuNP diameter of 14.5 nm. 
mTHPP layer number c (mTHPP) [µg/mL] 
 standard method modified method 
1 2.11 2.06 
2 4.73 3.30 
3 ------ 4.79 
5.4 Conclusion 
The aim was the preparation of surface-modified gold nanoparticles (AuNP) based 
on the LbL deposition technique with incorporation of the water-insoluble anticancer 
model drug mTHPP applied for PDT. For successful coating, a water-soluble 
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mTHPP/PSS complex was established remarkably increasing the solubility of the 
practical water-insoluble drug mTHPP by complex formation with the strong anionic 
polyelectrolyte PSS. By elemental analysis and by UV/vis spectroscopy, we could 
determine the number of PSS monomers (eleven) required for complexation of one 
mTHPP molecule. The mechanism behind the formation of stable drug polymer 
complexes was indicated by docking studies resulting in π-π interactions of benzene 
rings from PSS with the benzene and pyrrole rings of mTHPP, as well as H-bonds of 
OH- and NH-groups with the sulfonate groups. 
The LbL method was applied with PAH as the positively charged layer and the 
polyelectrolyte drug coadsorbate as the negatively charged layer. Five layers, three 
PAH and two complex layers, were adsorbed to the AuNP surface with the standard 
LbL method. A modified LbL procedure was developed to reduce the AuNP loss 
during the washing steps allowing for ten layers. The coating process was 
characterized by pH value determination, ζ-potential measurement, and recording of 
UV/vis spectra. The calculation of ABC(338-519 nm) allowed us to determine the 
adsorbed mTHPP concentration for one, two, and three adsorbed mTHPP layers. 
Regarding the gold concentration of 50 µg/mL, the mTHPP concentration of around 
2.1 µg/mL was adsorbed to the AuNP surface with the first complex layer which is 
equal to 1035 mTHPP molecules to 1 gold nanoparticle with a diameter of 14.5 nm. 
Surprisingly, it seems that the PAH coadsorbate complex was attached to the AuNP 
surface mainly as a random coiled structure and not the PSS/mTHPP coadsorbate in 
the stretched modification. An increase of ABC caused by mTHPP of at least 68% 
compared to the first drug layer adsorbed to AuNP surface could be clearly shown for 
every additional complex layer. All results have confirmed that mTHPP was 
successfully adsorbed onto the AuNP. The coating procedure developed allowed for 
the first time a drug-multilayer delivery system based on nanoparticles. 
Consequently, the drug concentration can be adjusted not only by the overall number 
of AuNP, but also by the number of repetitions of the complex layer. In this context, 
the formulation of the drug polyelectrolyte complex offered a completely new and 
comfortable method for drug incorporation in multilayer-coated nanoparticles. In 
comparison to the LbL technique, with pure PSS the PSS concentration used for 
coating with complex could be decreased considerably. This decrease yielded a 100 
fold increase of drug deposition efficiency. 
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5.5 Supporting information 
 
Table S1: Instrument parameters used for ICP OES measurements of colloidal 
gold solutions. 
Table S2: Complex characterization calculated with the obtained CHNS elemental 
analysis resultsin mass percentage [%] for carbon 48.68 ± 0.362, 
hydrogen 4.31 ± 0.113, nitrogen1.72 ± 0.038, and sulfur 10.37 ± 0.263 
(mean value ± standard deviation (S.D.)). 
Table S3: UV/Vis calibration of mTHPP in ethanol. 
Table S4: pH-value (mean value of pH-value, standard deviation (S.D.)) and ζ-
potential (meanvalue of zeta potential, standard deviation (S.D.)) of 
colloidal AuNP and surfacemodified AuNP solutions prepared by 
standard LbL method. 
 
 
 
Figure S1: Solubility enhancement of mTHPP in water as function mass of PSS 
added to 0.2 mgmTHPP, shown results after freeze drying and complex 
purification. 
Figure S2: Docking complex between PSS and mTHPP. 
Figure S3: CHNS elemental analysis (n=3) with setpoint as expected value and 
withmeasurement as measured value: A) of PSS, B) mTHPP. 
Figure S4: Calibration of AUC of mTHPP between 338 nm and 519 nm as function 
of mTHPPconcentration in ethanol. 
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Table S1: Instrument parameters used for ICP OES measurements of colloidal 
gold solutions. 
 
plasma 
gas 
nebu-
lizer gas 
nebu-
lizer 
spray 
cham-ber 
injector 
tube 
dia-
meter 
Slit 
 
Ana-
lysis 
mode 
Inte-
gration 
time 
Wave-
length 
[L/min] [L/min]   [mm] [µm]  [s] [nm] 
12 0.68 Mira 
Mist 
cyclonic 3 20x15 Gauss 0.5 242.795 
 
 
 
 
 
 
 
 
Table S2: Complex characterization calculated with the obtained CHNS elemental 
analysis results in mass percentage [%] for carbon 48.68 ± 0.362, 
hydrogen 4.31 ± 0.113, nitrogen 1.72 ± 0.038, and sulfur 10.37 ± 0.263 
(mean value ± standard deviation (SD)). 
parameter for complex values 
m(complex in 25 mL) [mg] ± SD 105.70 ± 0.885
mass percentage PSS [%] ± SD 77.85 ± 1.011
mass percentage mTHPP [%] ± SD 22.78 ± 0.170
recovery rate [%]± SD 100.64 ± 1.181
number of monomers pro mTHPP molecule ± SD 11.25 ± 0.062
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Table S3: UV/vis calibration of mTHPP in ethanol. 
lambda [nm] A = ε*c*d, ε*d = x [µg/mL] Coefficient of 
determination 
Measurement range 
[µg/mL] 
416.0 0.83128 0.9999 0.01 -    1
512.4 0.03019 0.9999 0.2   -  50
546.0 0.01082 0.9999    1.0  - 100
587.7 0.00871 0.9999    5.0  - 100
644.5 0.00493 0.9999  10.0  - 100
 
 
 
 
 
 
Table S4: pH-value (mean value of pH-value, standard deviation (SD)) and ζ-
potential (mean value of zeta potential, standard deviation (SD)) of 
colloidal AuNP and surface modified AuNP solutions prepared by 
standard LbL method. 
Sample (unwashed) pH-value ± SD ζ-potential [mV] ± SD 
AuNP 6.1 ±0.1 -39 ±1
AuNP(PAH)1 3.7 ±0.1 +33 ±6
AuNP(PAH/PSS+mTHPP)1 6.4 ±0.1 -60 ±2
AuNP(PAH/PSS+mTHPP)1PAH 3.9 ±0.1 +58 ±3
AuNP(PAH/PSS+mTHPP)2 6.2 ±0.1 -49 ±1
AuNP(PAH/PSS+mTHPP)2PAH 3.8 ±0.1 +56 ±3
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Figure S1: Solubility enhancement of mTHPP in water as function mass of PSS 
added to 0.2 mg mTHPP, shown results after freeze drying and 
complex purification. 
 
Figure S2: Docking complex between PSS (grey) and mTHPP (cyan). Hydrogen 
bonds and π-π interactions are drawn in black lines and distances are 
expressed in Å. Figures generated with MOE (Chemical Computing 
Group Inc., Montreal, Canada). 
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Figure S3: CHNS elemental analysis (n=3) with setpoint as expected value and 
with measurement as measured value: A) of PSS, B) mTHPP. 
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Figure S4: Calibration of AUC of mTHPP between 338 nm and 519 nm as function 
of mTHPP concentration in ethanol. 
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Abstract 
Many applied photosensitizers are characterized by a strong hydrophobicity and the 
induction of unrequested adverse reactions. The photosensitizer 5,10,15,20-
tetrakis(m-hydroxyphenyl)chlorin (mTHPC) is an approved anti-cancer drug for head-
and-neck cancer causing some adverse effects due to its formulation. Furthermore, 
mTHPC is known to be effective against a variety of tumor cells in vitro indicating 
future potential. Therefore, the administration and the following treatment are 
accompanied by severe difficulties including application problems. To overcome 
these kind of problems, the photosensitizer can be delivered by nanoparticles. In the 
present study, modified gold nanoparticles (mAuNP) were prepared by surface 
modification of citrate stabilized gold nanoparticles (AuNP) using the layer-by-layer 
(LbL) technique based on standard polyelectrolytes. The mAuNP and drug-loaded 
mAuNP with a size of 14 nm respectively were characterized regarding their physico-
chemical properties as well as the drug loading efficiency. The cellular 
characterization excluded a potential cytotoxicity of the unloaded mAuNP even at 
high concentrations. Furthermore, the cellular accumulation of unloaded and 
mTHPC-loaded mAuNP was shown and a drug release into the cells was assessed. 
Additionally, the activity of mTHPC-loaded mAuNP compared to free mTHPC was 
investigated. After illumination, the mTHPC-loaded mAuNP treated cells showed a 
decreased viability. First and foremost, dark toxic effects of the free photosensitizer 
could be reduced using mAuNP as drug carrier. To sum up, mAuNP are promising 
drug delivery systems for the hydrophobic photosensitizer mTHPC. 
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6.1 Introduction 
Photodynamic therapy (PDT) combines the administration of a photoinducable drug 
(photosensitizer) and the activation with light of a certain wavelength leading to cell 
death [1]. PDT facilitates a topical or local treatment of patients bearing different 
malignancies which often are tumors. After illumination highly reactive oxygen 
species, e.g., singlet oxygen (1O2) are generated destroying the surrounding tissue 
by apoptosis or necrosis. To achieve high rates of apoptosis efficient singlet oxygen 
quantum yields are needed. Therefore, high amount of photosensitizer must 
accumulate within the targeted tissue reaching effective and therapeutic intracellular 
concentrations. Nevertheless, PDT possesses certain administrable challenges and 
can cause burns, swelling, and pain [2]. 
The second generation photosensitizer 5,10,15,20-tetrakis(m-hydroxyphenyl)chlorin 
(mTHPC), which has been approved by the EMA in October 2001 for the palliative 
treatment of advanced head-and-neck-cancer [3], is characterized by a strong 
phototoxicity against a variety of human cancer cell lines in vitro [4]. Besides, it is 
known, that mTHPC possess a limited dark toxicity and can cause adverse effects 
especially caused by precipitation due to its strong hydrophobicity as well as its 
unspecific cellular accumulation [5, 6]. 
To enhance PDT efficiency and to overcome this obstacle, the usage of 
nanoparticulate systems is highly investigated [7]. Chatterjee et al. divided 
nanoparticle delivery systems for photodynamic therapy (PDT) in passive and active 
carriers for photosensitizer excitation[8]. Our focus is on passive carriers which are 
non-biodegradable and metallic. The usage of such nanoparticles results in different 
advantages such as well controlled synthesis, simple characterization techniques as 
well as uptake into cells without being recognized by efflux systems (e.g., P-
glycoprotein) resulting in an increased intracellular drug concentration [9]. A key 
advantage is the transport of hydrophobic drugs in the body, avoiding photosensitizer 
aggregation and loss of activity. Furthermore, the intravenously administered drug 
delivery systems can increase the tumor concentration of anti-tumor drugs up to 70-
fold due to the so-called enhanced permeability and retention effect (EPR effect) [10, 
11]. Nanoparticles as drug delivery systems offer several advantages including high 
drug-loading rates with marginal premature drug release as well as an efficient 
uptake by cancer cells through the EPR effect [12]. Tumors are characterized by 
leaky vasculature with pores of a size between 200 to 600 nm in diameter following 
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the fast hypervascularization, a decreased pH value and a weak lymphatic drainage 
compared to normal tissue [13]. All these properties enable high accumulation of 
nanoparticles and their retention in tumor tissue. 
Nanoparticles for PDT can be synthesized in different sizes and can act as 
multifunctional platforms through (I) a shell volume in which photosensitizers can be 
encapsulated or coupled, (II) a surface that can be functionalized to attach targeting 
groups for cancer specific drug accumulation, and (III) a contrast agent that can be 
incorporated for diagnostic reasons [7, 8]. 
To ensure maximum flexibility for the drug carrier, modular systems are most 
appreciated. An intriguing approach is based on the layer-by-layer (LbL) technique 
introduced by Decher et al. [14]. The LbL technique offers an endless variety of 
polyelectrolyte material and hence the preparation of tailored surfaces. As a core 
material, colloidal gold was chosen because of its optical properties, the intriguing 
size range in which monodisperse particles can be obtained, and its high chemical 
stability [15]. With respect to PDT, AuNP were also found to positively influence the 
singlet oxygen yield [16]. 
Here we described the preparation, characterization and cellular testing of mTHPC-
loaded modified gold nanoparticles (mAuNP) (Scheme 1). In this connection, the 
photosensitizer was complexed with poly(styrene sulfonate) sodium salt (PSS) and 
adsorbed onto the nanoparticle surface. First, the unloaded and mTHPC-loaded 
mAuNP were subjected to a physico-chemical characterization. Following, a potential 
cytotoxicity was investigated regarding high mAuNP concentrations, later the cellular 
binding and accumulation was proofed. Furthermore, we investigated the drug 
release into the cells and the efficiency of the mTHPC-loaded nanoparticles. 
 
Scheme 1: Layer-by-layer preparation of AuNP(PAH/PSS+mTHPC/PAH/PSS), 
PAH (MW 15.0 kDa), PSS (MW 4.3 kDa). 
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6.2 Materials and methods 
6.2.1 Materials 
The 5,10,15,20-tetrakis(m-hydroxyphenyl)chlorin, mTHPC (Mr 680.75 g mol-1), seen 
in Scheme 1 was kindly provided by biolitec AG (Jena, Germany). Gold (III) chloride 
hydrate (HAuCl4*3H2O), tri-sodium citrate-2-hydrate (Na3C6H5O7*2H2O), poly(styrene 
sulfonate) sodium salt (PSS) (MW 4.3 kDa) and poly(allylamine hydrochloride) (PAH) 
(MW 15.0 kDa) were purchased from Sigma-Aldrich (Steinheim, Germany). The 
water used in all experiments was prepared in a Millipore Milli-Q purification system 
(resistivity higher than 18.0 MΩ cm-1). 
 
6.2.2 Methods 
6.2.2.1 Preparation and characterization of PSS/mTHPC complex 
PSS/mTHPC complex was synthesized, purified, and characterized according to the 
procedure of Reum et al.[17] In brief, the complex was prepared by freeze-drying a 
liquid mixture of both compounds. The purification of the complex was realized by a 
combination of centrifugation and filtration. H-bonds and π – π interactions were the 
responsible forces of complex formation. For complexation of one mTHPC molecule, 
around 13 monomer units (4-ethylbenzenesulfonate sodium salt, 206.2 g mol-1) of 
one PSS (4300 g mol-1) molecule were necessary. 
 
6.2.2.2 Synthesis of AuNP 
Colloidal gold was synthesized as described before by the reduction of gold ions with 
citrate ions.[18] A volume of 99 mL of a tetrachlorauric acid (HAuCl4*3H2O) solution 
containing 20 mg (50.8 µmol) of gold salt were refluxed and 1 mL of sodium citrate 
solution containing 74.7 mg (254 µmol) of Na3C6H5O7*2H2O was added to the boiling 
solution. The solution was boiled for 20 min and cooled to room temperature. AuNP 
diameter determined by TEM with volume was 14 nm. The resulting suspensions had 
gold concentrations of 100 µg mL-1. 
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6.2.2.3 Preparation of PAH/PSS coated AuNP 
For encapsulation of colloidal gold nanoparticles, we used a slightly modified method 
formerly described by Decher[19] and Krol[20] using PAH and PSS. To 30 mL of the 
PAH solution (2.0 mg mL-1) was added 10 mL of unwashed-citrate-stabilized gold 
nanoparticle solution with a gold concentration of 100 µg mL-1, resulting in 136,500 
PAH chains per AuNP determined following Schneider et al.[21] After stirring for 
10 min, particles were separated from PAH excess by centrifugation at 8,515 g for 
15 h (Hettich Rotina 420 R, Hettich GmbH & Co. KG, Tuttlingen, Germany). The 
centrifuged nanoparticles were redispersed in water to a volume of 10 mL. The 
washing step was repeated once. Ten milliliters of PAH-coated AuNP were coated 
with 20 mL of PSS solution (1.17 mg mL-1) resulting in 91,000 PSS chains per AuNP. 
After incubation for 10 min, a sterile filtration (pore size: 0.2 µm, membrane material: 
cellulose acetate) was carried out with the AuNP(PAH/PSS) solution. Then the 
solution was centrifuged for 5 h at 9,612 g with a table centrifuge. Under a laminar 
flow cabinet the supernatant (29.850 mL) was removed and replaced by 3.350 mL of 
HT29 cell culture medium with 10% FCS to obtain a total volume of 3.50 mL of 
AuNP(PAH/PSS) solution with an Au concentration of around 150 µg mL-1 and a pH 
value of 7.5 (Table 1), applicable for in vitro cell testing. 
 
6.2.2.4 Preparation of (PAH/PSS+mTHPC/PAH/PSS) coated AuNP 
Similar to preparation of PAH/PSS coated AuNP, but as second layer instead of PSS, 
a complex consisting of PSS/mTHPC was used. The drug complex was applied in 
water at a concentration of 77.4 µg mL-1 PSS and 20.1 µg mL-1 mTHPC. To 20 mL of 
PSS/mTHPC complex was added 10 mL of AuNP(PAH), resulting in 15,000 PSS 
chains per AuNP. After stirring for 10 min the third polyelectrolyte layer (PAH) was 
adsorbed to AuNP(PAH/PSS+mTHPC). Therefore, to 20 mL of PAH solution with a 
concentration of 3.7 mg mL-1 was added the 30 mL of AuNP(PAH/PSS+mTHPC) 
solution, resulting in 206,000 PAH chains per AuNP. After stirring for 10 min, particles 
were separated from PAH excess by centrifugation at 24,400 g for 20 min (Hettich 
Rotina 420 R, Hettich GmbH & Co. KG, Tuttlingen, Germany). The centrifuged 
nanoparticles were redispersed in water to a volume of 25 mL. The washing step was 
repeated once and the nanoparticles were redispersed in water to a total volume of 
10 mL. PSS was used as last layer material with a concentration of 1.2 mg mL-1. To 
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20 mL of PSS solution was added 10 mL of AuNP(PAH/PSS+mTHPC/PAH) solution 
(per AuNP are 233,200 PSS chains available). After incubation for 10 min, a sterile 
filtration (pore size: 0.2 µm, membrane material: cellulose acetate) was carried out 
with the AuNP(PAH/PSS+mTHPC/PAH/PSS) solution. Then the solution was 
centrifuged for 20 min at 24,400 g with a table centrifuge. Under a laminar flow 
cabinet the supernatant (29.915 mL) was removed and replaced by 0.915 mL of 
HT29 cell culture medium with 10% FCS to obtain a total volume of 1.0 mL of 
AuNP(PAH/PSS+mTHPC/PAH/PSS) solution with an Au concentration of around 
300 µg mL-1 and a pH value of 7.5 (Table 1), applicable for in vitro tests. 
 
6.2.2.5 Transmission electron microscopy (TEM) measurements 
TEM measurements of the gold nanoparticles were performed on a JOEL model JEM 
2010 instrument (JOEL GmbH, Eching, Germany) operated at an accelerating 
voltage of 120 kV. Samples for TEM analysis were prepared by placing 12 µL of 
washed gold nanoparticle solution on a carbon-coated 400 mesh copper grid (S160-
4, Plano GmbH, Wetzlar, Germany). The suspensions were allowed to dry until the 
water was completely evaporated. Contrast agent was not applied. 
 
6.2.2.6 Particle size analysis 
The particle size analysis of TEM images was carried on ~ 100 particles using 
Image J. The real median diameter was determined. 
 
6.2.2.7 ζ-potential measurements 
The ζ-potential of uncoated, coated, and mTHPC loaded AuNP was determined by 
the principle of laser Doppler velocimetry with a Malvern Zetasizer Nano ZS (Malvern 
Instruments GmbH, Herrenberg, Germany). Measurements were realized in triplicate 
at 25 °C with the model of Smoluchowski. 
 
6.2.2.8 UV-visible spectroscopy measurements 
UV/Vis spectroscopy was carried out to check the successful polyelectrolyte and drug 
adsorption to AuNP surfaces. Furthermore, the adsorbed mTHPC mass to AuNP 
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surface was determined from the area between the curves (ABC). All measurements 
were carried out in 1 cm quartz cuvettes with the Perkin-Elmer Lambda 35 
Spectrophotometer (PerkinElmer LAS, Rodgau, Germany). 
 
6.2.2.9 Cell culture 
For all experiments the human colon carcinoma cell line HT29 (kindly provided by 
Indivumed, Hamburg, Germany) was used. HT29 cells were cultured at 37 °C and 
5 % CO2 in McCoy’s 5A medium (Promocell, Heidelberg, Germany) supplemented 
with 10 % fetal calf serum (PAA, Pasching, Austria) and antibiotics (50 U mL-1 
penicillin and 50 µg mL-1 streptomycin; Invitrogen, Karlsruhe, Germany). 
 
6.2.2.10 Determination of cell proliferation (BrdU assay) 
The cell proliferation was measured using the Cell Proliferation ELISA assay (BrdU 
(colorimetric); Roche Diagnostics, Mannheim, Germany). 5,000 cells were cultured in 
96 well plates (Greiner, Frickenhausen, Germany) and exposed to various 
concentrations (1, 10, 50 and 100 µg mL-1) of unloaded mAuNP in cell culture 
medium for 4, 24, 48 and 72 h (long time incubation) or 4 h followed by different 
persisting recovery times (24, 48 and 72 h) at 37 °C. Subsequently, the cells were 
washed once with cell culture medium and the determination of the cell proliferation 
was carried out according to the manufacturer’s instruction manual. The mean 
absorbance of untreated cells was defined as 100 % and the absorbance of the 
treated cells was related to this value. 2 % Triton X-100 treated cells were used as 
positive control. 
 
6.2.2.11 Determination of cell viability (WST-1 assay) 
Cell viability was determined with WST-1 assay (Cell Proliferation Reagent; Roche 
Diagnostics) that bases on the absorption measurement of formazan formation. 
5,000 cells were cultured in 96 well plates (Greiner) and exposed to various 
concentrations (1, 10, 50 and 100 µg mL-1) of unloaded mAuNP in cell culture 
medium for 4, 24, 48 and 72 h (long time incubation) or 4 h followed by different 
persisting recovery times (24, 48 and 72 h) at 37 °C. Subsequently, the cells were 
washed once with cell culture medium and the determination of cell viability was 
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carried out after addition of WST-1 reagent and the formazan formation was 
measured as described in the manufacturer’s instruction manual. The mean 
absorbance of untreated cells was defined as 100 %; the absorbance of the treated 
cells was related to this value. 2 % Triton X-100 treated cells were used as positive 
control. 
 
6.2.2.12 Determination of cell membrane integrity (LDH assay) 
The release of lactate dehydrogenase (LDH) was monitored with the Cytotoxicity 
Detection Kit (LDH; Roche Diagnostics). 5,000 cells were cultured in 96 well plates 
(Greiner) and exposed to various concentrations (1, 10, 50 and 100 µg mL-1) of 
unloaded mAuNP in cell culture medium for 4, 24, 48 and 72 h (long time incubation) 
or 4 h followed by different persisting recovery times (24, 48 and 72 h) at 37 °C. 
Subsequently, the cells were centrifuged (5 min, 1000 rpm, room temperature) and 
the supernatant was transferred into a new 96 well plate. The determination of the 
LDH leakage was carried out after addition of LDH substrate and the formazan 
formation was measured as described in the manufacturer’s instruction manual. The 
mean absorbance of 2 % Triton X-100 treated cells was defined as 100 % and the 
absorbance of the treated cells was related to this value. 
 
6.2.2.13 Determination of cellular accumulation 
Cells were cultured in 24 well plates (Greiner) and incubated with unloaded mAuNP 
concentrations (100 µg mL-1) for 24 up to 72 h at 37 °C. Following, the cells were 
washed twice with PBS and bright field pictures were taken of the cells. 
 
6.2.2.14 Scanning electron microscopy (SEM) 
Cells were cultured in µ-dishes (Ibidi, München, Germany) and incubated with 
unloaded mAuNP (100 µg mL-1) up to 72 h at 37 °C. Afterwards, the cells were 
washed with PBS and fixed over night at 4 °C with sodium cacodylate buffer 
containing 2 % glutaraldehyde. Following, the cells were incubated with 2 % osmium 
tetroxide, 1% tannic acid and 1% uranyl acetate. The cells were dehydrated in 
ethanol series and a critical point drying was performed. For microscopy analysis, the 
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samples were sputtered with gold and examined in a LEO 435 VP electron scanning 
microscopy (LEO Elektronenmikroskope GmbH, Oberkochen, Germany). 
 
6.2.2.15 Cellular uptake and intracellular distribution of free mTHPC and 
mTHPC-loaded mAuNP 
Cellular uptake and intracellular distribution was analyzed using confocal laser 
scanning microscopy (CLSM) and multiphoton laser scanning microscopy (MP-LSM). 
125,000 cells were seeded into chamber slides (CultureSlides, Becton Dickinson) 
and incubated for 24 h at 37 °C. For 24 h the cells were treated with both, free 
mTHPC (3 µg mL-1) and two concentrations mTHPC-loaded mAuNP (mTHPC 
concentration: 3 and 9 µg mL-1) in the dark at 37 °C, respectively. Following, the cells 
were washed twice with PBS and the membrane was stained with concanavalin A 
Alexa Fluor 488 (50 µg mL-1, Invitrogen). After fixation, the cells were washed again 
and embedded in Vectashield HardSet Mounting Medium (Axxora, Grünberg, 
Germany) and analyzed using a confocal laser scanning microscope (Axiovert 200 M 
microscope with a 510 NLO Meta device, Zeiss, Jena, Germany) with argon ion and 
chameleon laser (providing fs laser pulses at a repetition rate of 80 MHz at 
λ = 800 nm for AuNP excitation) and the LSM Image Examiner software. 
 
6.2.2.16 Determination of cell viability after PDT treatment 
Cell viability was determined with WST-1 assay (Cell Proliferation Reagent, Roche 
Diagnostics) after incubation with mTHPC-loaded mAuNP. 15,000 cells were cultured 
in 96 well plates (Greiner) and exposed to free and bound mTHPC (3 µg mL-1) in cell 
culture medium for 4 and 24 h at 37 °C. Subsequently, the cells were washed once 
with cell culture medium and either illuminated with 5 J cm-2 (at a fluence rate of 
10 mW cm-2 for 500 s) or kept in the dark as dark control. After 1 h recovery at 37 °C, 
the determination of cell viability was carried out as previously described. 
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6.3 Results and Discussion 
6.3.1 Synthesis of Gold nanoparticles (AuNP) 
Colloidal gold prepared by redox reaction of gold (III) chloride hydrate and tri-sodium 
citrate-2-hydrate was characterized by transmission electron microscopy (TEM) and 
showed a monodisperse size distribution with a median particle diameter of 14.1 nm 
and a standard deviation of 1.1 nm (Figure 1, Table 1). As expected the ζ-potentials 
of citrate stabilized AuNP showed negative values (-33 ± 3 mV) because of the citrate 
ions on the surface of AuNP [21]. 
AuNP size distribution by TEM image
d(TEM) = 14.1 nm (SD = 1.1 nm) V41
0
2
4
6
8
10
0 5 10 15 20 25 30
diameter [nm]
fre
qu
en
cy
BA
 
Figure 1: (A) TEM image of citrate stabilized AuNP, (B) Size distribution of citrate 
stabilized AuNP (analysis of the TEM image with Image J). 
 
With the help of equation (1) from Haiss et al. [22], based on UV/Vis absorption data, 
we could also calculate the AuNP diameters obtaining a value of 13.1 ± 1.2 nm which 
is in very good agreement with the result by TEM measurement. 
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with d the diameter of the particles in nanometer (for 5 nm ≤ d ≤ 30 nm), cAu the gold 
concentration (mol L-1), ASPR the absorbance at the surface plasmon resonance of 
AuNP solution, and C1 = -4.75, C2 = 0.314 being specific constants. 
 97 
  Chapter 4 
6.3.2 Characterization of mAuNP (AuNP(PAH/PSS)) 
Schema 1 depicts the principle of PAH/PSS loaded AuNP preparation with the layer-
by-layer deposition technique. For the drug-free AuNP(PAH/PSS) the Schema 1 was 
slightly simplified because only two polyelectrolyte layers were adsorbed on the 
AuNP surface and instead of PSS/mTHPC complex for the second layer, pure PSS 
was used. As first layer, PAH was adsorbed, therefore, the ζ-potential was inverted 
(to positive value) with respect to the citrate-stabilized AuNP (Supporting Information) 
[21]. The typical absorption spectrum of citrate-stabilized AuNP (black dashed line) 
and the respective absorption curves after surface modification is shown in Figure 2 
A. The peak near 520 nm is caused by surface plasmon resonance [20] of AuNP 
allowing a straightforward characterization [23]. The adsorption of PAH led to a little 
red shift of the AuNP peak of 1 - 2 nm due to change of the surrounding refractive 
index induced by the adsorbed polyelectrolyte PAH and a broadening of the peak on 
the right side (blue solid line in Figure 2 A). The adsorption of the second layer, PSS 
resulted in a negative ζ-potential of -46 mV (Supporting Information, Table 1), as 
expected. Sterile filtration and one centrifugation step of modified AuNP resulted still 
in negative ζ-potential values (-49 mV). The ζ-potential of AuNP(PAH/PSS) in 
medium was decreased to a value of around -10 mV caused by a higher ion 
concentration and proteins compared to pure water (Supporting Information, Table 
1). The red shift and the broadening were obtained with every further adsorbed layer. 
This behavior was also found after dispersing AuNP(PAH/PSS) in cell culture 
medium (red to green solid line). This red shift of the plasmon peak to 528 nm is a 
hint for protein attachment on the nanoparticle surface [24, 25] from the cell culture 
medium. 
 
6.3.3 Characterization of mAuNPdrug (AuNP(PAH/PSS+mTHPC/PAH/PSS)) 
Schema 1 depicts the principle of mTHPC-loaded mAuNP preparation with the layer-
by-layer deposition technique. The complex composed of PSS and mTHPC was 
successfully formed [17] and was adsorbed as second layer. Schneider et al.[17] 
identified that 60,000 polyelectrolyte (PE) chains per AuNP resulted in the highest 
single, non- aggregated mAuNP yield. Here, however, only 15,000 PSS chains were 
available per AuNP. The idea behind this was to reduce the excess material and to 
increase deposition efficiency [26]. Adsorbing the polyelectrolyte drug complex 
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changed the ζ-potential to a negative value of -52 mV (Supporting Information). As 
third layer, PAH was deposited again, reversing the ζ-potential to a positive value of 
66 mV. The fourth and last PE layer was pure PSS resulting in a ζ-potential of            
-41 mV (Supporting Information, Table 1). Transferring the particles into cell culture 
medium containing fetal calf serum (FCS) resulted as before in a decrease of the ζ-
potential to a value of -10 mV (Supporting Information, Table 1). This reduction of the 
ζ -potential is due to protein adsorption to the surface [24, 25]. However, the course 
of the ζ-potential values indicates that all four layers were coated to the AuNP 
surface. 
UV/Vis spectroscopy also allowed controlling the coating steps. The absorption 
spectrum of AuNP(PAH/PSS+mTHPC/PAH/PSS) is presented in Figure 2 C. 
Compared to the UV/Vis spectrum of AuNP(PAH) a red shift of AuNP peak of 4 nm 
and a stronger broadening of the peak on the right side due to the three further layers 
were observed. More interestingly, the spectrum indicates an additional peak near 
420 nm originating from mTHPC (Figure 2 B) deposited as a complex on the AuNP 
surface. The stability, which is crucial for application in cell culture, was controlled by 
the flocculation level introduced by Weisbecker et al. [27] not showing agglomeration 
of the modified AuNP. 
 
Figure 2: UV/Vis spectra in water: (A) of modified AuNP: layer 0 ≙ citrate-
stabilized AuNP; layer 1 ≙ AuNP(PAH); layer 2 ≙ AuNP(PAH/PSS); 
layer 2 medium ≙ AuNP(PAH/PSS) in cell culture medium; (B) of 
PSS/mTHPC complex (orange line) and mTHPC in ethanol (blue line); 
(C) of modified AuNP: layer 0 ≙ citrate-stabilized AuNP; layer 1 ≙ 
AuNP(PAH); layer 4 ≙ AuNP(PAH/PSS+mTHPC/PAH/PSS). 
The knowledge about the drug concentration adsorbed to the mAuNP is essential for 
application. A previously developed method, based on the calculation of the area 
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between the curves (ABC) between 338 nm and 519 nm of AuNP(PAH) and 
AuNP(PAH/PSS+mTHPP/PAH/PSS), was applied to estimate the mTHPC 
concentration [26]. However, the method was adapted for mTHPC. For calibration of 
the ABC, twice washed AuNP(PAH) were added to different known concentrations of 
PSS/mTHPC complex (Figure 3). For calibration, the ABC of mTHPC between 
338 nm and 519 nm as function of the mTHPC concentration in the drug complex in 
water was recorded (Figure 3B). For linearity of the calibration curve an acceptable 
value of R2 = 0.9918 was obtained. The mTHPC concentration adsorbed to AuNP 
determined for a gold concentration of 50 µg mL-1 was 1.506 µg mL-1 for the 
AuNP(PAH/PSS+mTHPC/PAH/PSS). 
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Figure 3: (A) UV/Vis spectra of mixtures of twice washed AuNP(PAH) (≙ layer 1) 
and different known concentrations of PSS/mTHPC complex (≙ layer 2) 
in water; (B) UV/Vis calibration of ABC of mTHPC between 338 nm 
and 519 nm as function of mTHPC. 
 
To obtain higher mTHPC concentrations, the AuNP solution was concentrated by 
centrifugation to an Au concentration of 300 µg mL-1, and 9.036 µg mL-1 mTHPC 
(Table 1), respectively. A further possibility to enhance the drug concentration 
adsorbed to one AuNP are drug multilayers [26]. Typical tissue concentrations tested 
on several carcinoma cell lines for efficient tumor treatment with mTHPC are around 
1.0 µg mL-1 indicating that the concentration on the particles would be high enough 
for application [28-30]. 
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Table 1: Characterization of modified drug-free and drug-loaded AuNP with drug-
free ≙ AuNP(PAH/PSS) and drug-loaded ≙ 
AuNP(PAH/PSS+mTHPC/PAH/PSS); the core diameter is the median 
diameter of pure AuNP determined by TEM measurement; the number 
of layers are the numbers of the polyelectrolytes and complex adsorbed 
to AuNP surface; the outer layer is the last polyelectrolyte layer 
adsorbed to AuNP surface; the ζ-potential in water is of the 
complemented layered AuNP, measured in water; the ζ-potential in cell 
medium is of the complemented layered AuNP, measured in HT29 cell 
culture medium; c(Au) is the Au concentration of modified AuNP in HT29 
cell culture medium; c(mTHPC) is the mTHPC concentration adsorbed to 
AuNP surface of modified AuNP in HT29 cell culture medium; pH value 
is of the HT29 cell culture medium with the corresponding modified 
AuNP. 
sample name (mAuNP) (PAH/PSS) (PAH/PSS+mTHPC/PAH/PSS) 
core diameter by TEM [nm] 14 14 
number of layers 2 4 
outer layer PSS PSS 
ζ-potential in water [mV] -46 -41 
ζ-potential in cell medium [mV] -10 -10 
c(Au) [µg mL-1] 150 300 
c(mTHPC) [µg mL-1] 0 9 
pH value 7.5 7.4 
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6.3.4 Determination of cytotoxicity after long time incubation with 
mAuNP 
In a first cellular experiment, the effects of unloaded mAuNP following different 
incubation times (4-72 h) on the used human colon carcinoma cell line HT29 were 
analyzed. For all experiments the cells were incubated with different concentrations 
of unloaded mAuNP (0-100 µg mL-1). Three different cytotoxicity assays (BrdU, WST-
1, LDH assay) were performed with these parameters. 
The cell proliferation was determined using the Cell Proliferation ELISA assay that is 
based on the incorporation of the base analogue BrdU (5-bromo-2-deoxyuridine) 
during DNA-synthesis. HT29 cells showed a time- and concentration-dependent 
decrease in cell proliferation leading to 40 % (72 h, 100 µg mL-1) active cells for the 
highest AuNP concentration (cAu) compared to control cells (Figure 4 A). Shorter 
incubation times (4 and 24 h) did not have any effects on cell proliferation. After 48 h 
continuous exposure of mAuNP first declines in cell proliferation could be observed. 
In addition, the measured cell viability mainly remained constant during the testing 
phase (Figure 4 B). The used viability assay based on the reduction of the WST-1 
salt by metabolic active cells leading to a formazan formation meaning the values 
were proportional to the amount of cells with mitochondrial activity. The cells showed 
minor fluctuations in cell viability caused by mAuNP and overall the cell viability was 
not strongly different from untreated control cells. These findings were in accordance 
with previous studies. Amongst others, Hauck et al. [31] tested the toxicity of different 
surface modified gold nanorods on HeLa cells and found that a coating with PSS had 
no significant influence on the cell viability. 
A possible damage of the cell membrane after incubation with mAuNP was 
investigated using the LDH leakage assay. The presence of higher concentrations of 
the stable cytosolic enzyme LDH (lactate dehydrogenase) in the supernatant is only 
possible having reduced cell membrane integrity. HT29 cells showed nearly no 
effects after the nanoparticle incubation (Figure 4 C). The LDH release varied only 
marginally for all tested mAuNP concentrations and incubation times. Since there 
was no increasing LDH release, we assume that unloaded mAuNP did not disturb or 
destroy the cell membrane even at higher concentrations (100 µg mL-1). 
Our findings concerning cell viability and membrane integrity were consistent with 
previous studies in which PSS modified gold nanorods were shown to be non toxic 
[32]. Leonov et al. concluded that PSS can act as detoxification agent against 
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cetyltrimethyl ammonium bromide (CTAB) and shows no toxic effects on treated cells 
[32]. 
In conclusion, short time incubations (4 and 24 h) with mAuNP did not induce any 
cellular changes in cell viability, cell proliferation or membrane integrity. Longer 
incubation time had a certain effect on cell proliferation but not on cell viability and 
membrane integrity. Additionally, our results were in accordance with previous 
studies regarding the size-dependent cytotoxicity of AuNP by Pan et al. [33]. They 
found that 15 nm AuNP in size were non-toxic compared to smaller nanoparticles in 
size. It has to be mentioned that Pan et al. [33] used citrate stabilized AuNP for the 
trials, which were the core materials for the mAuNP. 
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Figure 4: Determination of cytotoxic effects of unloaded mAuNP after long time 
incubation: HT29 cells were exposed to an increasing concentration of 
unloaded mAuNP (0-100 µg mL-1) for 4, 24, 48 and 72 h at 37 °C. 
A: BrdU assay, B: WST-1 assay, C: LDH assay Each result represents 
the mean value ± standard deviation (SD) of three experiments. 
Untreated cells were used as negative control and 2 % Triton X-100 
treated cells as positive control. 
 
6.3.5 Determination of after-effects following unloaded mAuNP 
incubation 
After demonstration, that unloaded mAuNPs did not affect the cells even at higher 
concentrations, HT29 cells were tested concerning possible after-effects. Following a 
short incubation of 4 h (0-100 µg mL-1), the cellular response after different recovery 
phases (24, 48 and 72 h) was tested, to see whether the cells will respond to a 
previous incubation. Therefore, HT29 cells were incubated with increasing unloaded 
mAuNP concentrations (0-100 µg mL-1) and the cytotoxicity was evaluated after 
different rest periods. The cell proliferation (Figure 5 A) showed fluctuations after 
incubation with the different concentrated unloaded mAuNP. 24 h after mAuNP 
exposure, the cell proliferation was nearly constant for all mAuNP concentrations. An 
increasing cell proliferation could be detected after a rest period of 48 h. After 72 h 
rest period, the cell proliferation declined and reached levels comparable to the 
control cells. 
Initially, the cell viability increased in a concentration- and time- dependent manner 
(Figure 5 B) but aligned with the control cells after a 72 h rest period. 
HT29 cells showed nearly no effects concerning a membrane damage after the 
unloaded mAuNP incubation (Figure 5 C). The LDH release varied only marginally for 
all tested concentrations and incubation times. Only the control cells showed a 
slightly increased LDH leakage. 
In conclusion, the results of the assays revealed no cytotoxic after-effects of the 
tested unloaded mAuNP after incubations times up to 72 h. A short time contact of 
cells with the tested nanoparticles did not cause cytotoxic effects. Therefore, an 
application of mAuNP with PSS as outermost layer as drug delivery system is 
promising with respect to their acute toxic profile. 
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Figure 5: Determination of after-effects following unloaded mAuNP 
incubation.HT29 cells were exposed to an increasing concentration of 
unloaded mAuNPs (0-100 µg mL-1) for 4 h at 37 °C, followed by a rest 
period from 24 h up to 72 h. Cell proliferation (A; BrdU assay), cell 
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viability (B; WST-1 assay) and membrane integrity (C; LDH assay) were 
measured with the corresponding assays as described in the 
experimental section. Each result represents the mean value ± standard 
deviation (SD) of three experiments. Untreated cells were used as 
negative control and 2 % Triton X-100 treated cells as positive control. 
 
6.3.6 Cellular accumulation of unloaded mAuNP 
The results of the different cytotoxicity assays revealed neither cytotoxic effects even 
at high mAuNP concentrations nor after-effects following short time contacts with 
unloaded AuNPs. Therefore, the cellular accumulation of the mAuNP was 
investigated. HT29 cells were incubated with the highest mAuNP concentration 
(100 µg mL-1) for 24 to 72 h. Following, the cellular accumulation was analyzed with 
bright field microscopy and scanning electron microscopy (SEM). 
The results of bright field microscopy revealed a time-dependent accumulation of 
mAuNP. HT29 cells showed over time an increasing amount of red colored clusters 
caused by enriched mAuNP assumedly on the cell surface (Figure 6). The incubation 
led to a cluster formation and red staining but the cellular localization of the 
nanoparticles could not be shown with this method. 
Due to the high number of electrons in gold atoms the detection of AuNP with SEM is 
possible. Therefore, the cellular binding or accumulation respectively was determined 
using scanning electron microscopy (SEM). SEM analysis was performed with both 
secondary electrons (SE) and backscattered electrons (BSE). Accordingly, HT29 
cells were incubated with mAuNP (100 µg mL-1) for 24-72 h and the cellular 
accumulation was investigated. 
Accumulated mAuNP clusters appeared as white clusters on the cell surface. After 
an incubation time of 24 h, mAuNP clusters on the cell surface could be detected 
(Figure 6). The same clusters appeared after 48 and 72 h incubation. The achieved 
results were consistent with bright field results. By using a SE, the achieved 
information was mainly pertaining to the cellular morphology. To further contrast the 
mAuNP clusters, a QBSD-detector was used as backscattered electrons contain 
information about material properties. They arise in deeper regions of the substrate 
and depend on the involved elements. After detection and collecting of the 
backscattered electrons, the clusters appeared bright white. Again, the clusters 
mainly arranged on the cell surface. There was no evidence that the mAuNP are 
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taken up by the cells. Additionally, the SEM analysis of treated HT29 cells revealed 
no morphological changes of HT29 cells after incubation verifying the non-toxic 
potential of unloaded mAuNP. 
 
Figure 6: Determination of cellular accumulation of unloaded mAuNP (100 µg mL-1) 
for 24 up to 72 h at 37 °C. Following, bright field and scanning electron 
microscopy images of the cells were taken. For SEM, two detectors for 
visualization were used: morphology (SE; secondary electron detector) 
and material (BE; quadrant back scattered electron detector). 
 
6.3.7 Cellular uptake and intracellular distribution of mAuNP 
Since the previous results did not clarify the question if mAuNPs were taken up by 
the cells, further tests with unloaded mAuNPs were carried out. For this, the cellular 
uptake and intracellular accumulation was investigated using CLSM (confocal laser 
scanning microscopy) and MP-LSM (multiphoton laser scanning microscopy) relying 
on the ability of colloidal gold to be visualized by multiphoton excitation [34, 35]. 
Accordingly, HT29 cells were incubated with mAuNP (100 µg mL-1) and mTHPC-
loaded mAuNP (applied mTHPC concentration: 3 or 9 µg mL-1) for 24 h at 37 °C. 
After membrane staining and fixation, the analysis was carried out. 
First, the signal of accumulated unloaded mAuNP was analyzed using MP-LSM. 
Signals of mAuNP appeared inside of the cells (Figure 7 A). To confirm the achieved 
signals, phase contrast pictures were taken and the positions of the signals by MP-
LSM and phase contrast were compared (Figure 7 B & C). Accumulated mAuNP 
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appeared as dark clusters in phase contrast and matched the position received in the 
multiphoton-based analysis. Consequently, it was possible to detect the accumulated 
mAuNP within the cells. 
After demonstrating the functionality of the method, the cellular accumulation of 
mTHPC-loaded mAuNP was investigated to proof the release of the complexed 
photosensitizer. (Figure 7 D & G). Furthermore, mTHPC-loaded mAuNP were tested 
with regard to a cellular accumulation of the nanoparticles and mainly on the release 
of mTHPC into the cytoplasm (Figure 7 D & G; 3 and 9 µg mL-1 mTHPC 
concentration) for 24 h. The release of the photosensitizer mTHPC into the cytoplasm 
was assessed for both concentrations (Figure 7 D & E, G & H). The incubation with 
both concentrations led to the typical mTHPC fluorescence within the whole 
cytoplasm [4, 30]. Cells incubated with 3 µg mL-1 free mTHPC possessed a slightly 
higher fluorescence signal within the cells compared to cells treated with mTHPC-
loaded mAuNP. Nevertheless, these cells were characterized by a changed 
morphology (Supporting Information). In some cellular regions, the characteristic 
AuNP-signal could be observed (arrows indicating position). The nanoparticles stuck 
either on the outer cell membrane as previously shown by SEM or were located 
within the cells. In both cases, the drug was released from the mTHPC-loaded 
mAuNP. Consequently, the incorporated drug was transported within the cells via the 
nanoparticles and there, mTHPC was released from the formulation leading to the 
staining of the complete cytoplasm. The morphology of the treated cells appeared 
unchanged. Instead, HT29 cells incubated with free mTHPC (3 µg mL-1) showed also 
a strong intracellular mTHPC distribution, but the cells lost their typical structure. The 
cell shape was mostly round indicating cell death (Supporting Information) and a 
dissolving process of the cells started due to the toxic effects of the drug. HT29 cells 
incubated with the nanoparticulate formulation kept their typical morphology. No 
changes in the shape could be observed. 
In conclusion the nanoparticulate bound drug was successfully delivered by mTHPC-
loaded mAuNP into HT29 cells. There, it was released into the cytoplasm. The 
cellular morphology remained normal compared to cells treated with free mTHPC. 
The toxic effects of mTHPC on HT29 cells could be reduced by adsorbing the drug to 
the surface of mAuNP. 
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Figure 7: Cellular uptake and intracellular distribution of unloaded and mTHPC-
loaded mAuNP. HT29 cells were cultured on glass slides and incubated 
with unloaded mAuNP (A-C: 100 µg mL-1) or mTHPC-loaded mAuNP 
(D-F: 3 µg mL-1 mTHPC concentration; G-I: 9 µg mL-1 mTHPC 
concentration) for 24 h at 37 °C. For visualization, the cell membrane 
was stained with concanavalin A Alexa Fluor 488 (green). The MP-LSM 
based mAuNP signal was used for detection (yellow). Pictures were 
taken within inner sections of the cells. (A) mAuNP signal (yellow); (B) 
phase contrast picture of the cells, and (C) overlay of phase contrast 
picture and mAuNP signal. Arrows indicate mAuNP cluster. (D) 
Accumulation of mTHPC-loaded mAuNP, 3 µg mL-1 mTHPC 
concentration and (G) accumulation of mTHPC-loaded mAuNP, 
9 µg mL-1 mTHPC concentration, and (E, H) accumulation of free 
mTHPC, and (F, I) mAuNP signal. Arrows indicate mAuNP clusters. 
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6.3.8 Determination of phototoxicity of free and mAuNP-bound mTHPC 
In the final experiment, the in vitro efficiency of the mTHPC-loaded mAuNP 
compared with free mTHPC was determined. No further trials regarding a potential 
cytotoxicity of mTHPC-loaded mAuNPs were carried out because PSS was again the 
outermost layer. In preceding experiments, we already showed the non-toxic effects 
of PSS coated mAuNP. Therefore, HT29 cells were incubated either with free 
mTHPC (3 µg mL-1) or mTHPC-loaded mAuNP (applied mTHPC concentration: 
3 µg mL-1) for 24 h. To survey the functionality of the bound mTHPC, the cell viability 
was determined using the WST-1 assay after illumination (652 nm; 5 J cm-2). Dark 
toxic effects of both, the free drug and the nanoparticulate formulation were 
determined without illumination in the same experiment. 
First, dark toxic effects of both drugs were analyzed. After 4 h exposure, both drugs 
induced a slightly increased cell viability compared to untreated control cells (Figure 
8 A). By increasing the incubation time up to 24 h, dark toxic effects of the free 
photosensitizer could be detected indicated through reduced cell viability. The 
mTHPC-loaded mAuNP induced only a weak reduction in cell viability (to 83 %) even 
after 24 h incubation. Consequently, the nanoparticulate system reduced the dark 
toxicity of the drug compared to the free photosensitizer. Here, we could demonstrate 
that the nanoparticulate system could reduce toxic adverse effects of a drug which 
has been shown for another delivery system earlier [36].Kiesslich et al. compared the 
efficiency and dark toxicity of free and liposomal bound mTHPC. They found a 
reduced dark toxicity of the liposomal formulation compared to free mTHPC. Our 
results concerning a reduced dark toxicity of the novel synthesized systems were 
consistent with these findings. 
After illumination, a decrease of cell viability could be observed for both, free and 
nanoparticulate-bound mTHPC (Figure 8 B). Free mTHPC caused a strong decline in 
cell viability (to ~7 %) after both incubation times. The nanoparticulate-bound mTHPC 
provoked decreased cell viability (to 48 %) only after a longer incubation time of 24 h. 
Four hours incubation did not effect the cells due to the structure of the 
nanoparticles, two polyelectrolyte layers covering the photosensitizer. The 4 h 
exposure time was not sufficient enough to enable cellular uptake and diffusion of 
mTHPC molecules from the mTHPC-loaded mAuNP into the cells. Consequently, the 
amount of available mTHPC was too low to affect the cells. After prolongation the 
exposure time up to 24 h, the viability after treatment with mTHPC-loaded mAuNP 
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decreased to 48 % viability indicating that many cells had been killed through 
photodynamic action. The cellular uptake and the local diffusion of mTHPC through 
the layer material enabled efficient drug release and a successful treatment. It is 
conceivable that after 24 h not the entire nanoparticulate-bound drug has been 
released into the cytoplasm leading to a reduced but not comparable reduction of cell 
viability. A prolongation of the exposure time could most likely increase the amount of 
dead cells due to an increased free drug concentration. 
 
Figure 8: Determination of phototoxicity of free and bound mTHPC. HT29 cells 
were exposed to free mTHPC or mTHPC-loaded mAuNP 
(corresponding to a mTHPC concentration of 3 µg/mL and an AuNP 
concentration of 100 µg mL-1) for 4 h and 24 h followed by illumination 
(652 nm; 5 J cm-2, 500 s). The cell viability was measured by WST-1 
assay as described in the experimental section. Each result represents 
the mean viability ± standard deviation (SD) of three experiments. Cell 
viability was calculated as percentage of viable cells compared to 
untreated control cells. Untreated cells were used as negative control 
(CDC: dark control cells; CIll: illuminated control cells) and 2 % Triton X-
100 (2 % TX) treated cells as positive control. 
 
6.4 Conclusion 
In conclusion, our results emphasize the usage of modified gold nanoparticles 
(mAuNP) as drug delivery system for the hydrophobic photosensitizer mTHPC. A 
modification of citrate-stabilized AuNP with an adapted layer-by-layer technique 
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resulted in stable non-toxic mAuNP. AuNP with PSS as outer layer were taken up by 
HT29 cells and the mTHPC was released delayed. It could be shown that the 
incorporation of the photosensitizer into the surrounding layers led to reduction of 
dark toxicity compared to free mTHPC. The phototoxicity of mTHPC-loaded mAuNP 
was demonstrated. Caused by the delayed release of mTHPC, the efficiency after 24 
hours was 50 %, compared to free mTHPC with 90 % efficiency. The reduced dark 
toxicity in combination with the delayed release could be a huge advantage 
considering adverse effects due to free mTHPC in healthy tissue. A further 
modification of mTHPC-loaded mAuNP with cancer cell type specific ligands, such as 
antibodies, could enable a higher and more specific accumulation of such mAuNP in 
tumor cells compared to mAuNP without such antibodies. 
 
 
6.5 Supporting information 
 
 
Figure S1: Zeta potential: A) of modified AuNP; B) of modified AuNP with drug: 
number is equal to the layer number of unwashed modified AuNP in 
water* once washed modified AuNP in water, ** twice washed modified 
AuNP in water, M: modified AuNP dispersed in cell culture medium of 
HT29 cells. 
Figure S2: Cellular uptake and intracellular distribution of free mTHPC. HT29 cells 
were cultured on glass slides and incubated with free mTHPC (3 µg mL-1) 
for 24 h at 37 °C. For visualization, the cell membrane was stained with 
concanavalin A Alexa Fluor 488 (green). (A, B) mTHPC accumulation in 
HT29 cells (red); (C) phase contrast picture of the cells. 
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Figure S1: ζ-potential: A) of modified AuNP; B) of modified AuNP with drug: number 
is equal to the layer number of unwashed modified AuNP in water* once 
washed modified AuNP in water, ** twice washed modified AuNP in 
water, M: modified AuNP dispersed in cell culture medium of HT29 cells. 
 
 
 
 
 
Figure S2: Cellular uptake and intracellular distribution of free mTHPC. HT29 cells 
were cultured on glass slides and incubated with free mTHPC (3 µg mL-1) 
for 24 h at 37 °C. For visualization, the cell membrane was stained with 
concanavalin A Alexa Fluor 488 (green). (A, B) mTHPC accumulation in 
HT29 cells (red); (C) phase contrast picture of the cells. 
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7 Overall Conclusion and Outlook 
Photodynamic therapy (PDT) combines photosensitizer, visible light, and tissue 
oxygen for treatment of superficial tumors and non-cancerous diseases. The 
advantages of PDT are its high selectivity, minimal invasiveness, low side effects, 
and allowing for repetitive application. For non-dermatological applications, the 
photosensitizers are delivered systemically, which results in several problems caused 
by their typically high hydrophobicity. The selective therapeutic effect against tumor 
tissues can be provided by the structure of drugs and tumor physiology, especially 
the enhanced permeability and retention (EPR) effect. Improved targeting of 
photosensitizers would help to prevent the damage to the surrounding healthy tissue 
and lowering dose of drugs. Therefore, the use of nanotechnology in photosensitizer 
delivery is an attractive approach. 
Recently published advances in the use of nanotechnology for PDT application 
include formulations of biodegradable and non-degradable nanoparticles as passive 
carriers for photosensitizing agents as well as active carriers which are characterized 
by attachment of specific ligands such as peptides, antibodies, aptamers, or small 
molecules to the nanoparticle surface. 
In this study, non-degradable nanoparticles as passive carrier for the practically 
water insoluble photosensitizer (PS) 5,10,15,20-tetrakis(3-hydroxyphenyl)chlorin 
(mTHPC) or its model PS 5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrin (mTHPP) 
were developed and investigated. The drug mTHPC is approved in head and neck 
cancer and has a promising potential to be applied in a lot of other diseases. As 
template for the development of surface modified nanoparticles with the so-called 
layer-by-layer (LbL) technology served gold nanoparticles (AuNP) with a diameter of 
around 15 nm. 
For AuNP loading with the drug, a complex consisting of the negatively charged layer 
material poly(styrene sulfonate) sodium salt (PSS) and mTHPC was generated. The 
complex was characterized by its water solubility and therefore, the dramatically 
increased water solubility of mTHPC. The interactions between both molecules were 
indentified and π-π interactions and H-bonds were the responsible mechanism for 
the complex formation. Furthermore, the complexation efficiency was determined 
with ~12 monomer units or 4-ethyl(styrene sulfonate) sodium salt units of PSS per 
mTHPC molecule independent of the PSS molecular weight. The photophysical 
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characterization of the complex resulted in a decreased singlet oxygen quantum yield 
of the complex compared to free mTHPC but in an increased phototoxicity tested 
with Jurkat cells. No toxicity of PSS could be observed in vitro indicating that the 
PSS/mTHPC complex has great prospects to become a potential drug delivery 
system for mTHPC, especially due to its simple and quick preparation. 
For targeting of the complex and a potential reduced sensitivity to light the loading of 
nanoparticles was in the focus. Therfore, AuNP were surface modified by the 
attachment of the PSS/drug complex to the AuNP surface using the LbL technology. 
This approach would also allow a precise drug adjustment other than the pure 
number of particles. As positively charged layer material was used the extensively 
studied poly(allylamine hydrochloride) (PAH) and instead of the negatively charged 
polyelectrolyte PSS, the complex was utilized. By repeating these coating steps, the 
first drug-multilayered nanoparticulate formulation was prepared. By the way, the 
drug deposition efficiency was increased by the factor of 100 compared to standard 
LbL technique. Around 1000 drug molecules were attached to the surface of one 
AuNP with one complex layer. Additionally, it seems that the structure of the 
complex, which is adsorbed as complex with PAH on the AuNP surface, is in a 
random coiled structure. This insight could be gained estimating the amount of 
adsorbed polyelectrolyte in comparison with the determined amount of drug which 
has a fixed ratio to the carrier. 
To clarify the potential of mTHPC loaded AuNP in medicine, detailed cellular 
investigations were carried out. The influence of the drug-free carrier system with 
PSS as outer layer on the HT29 cells, based on the BrdU-, WST-1-, and LDH-assay 
was investigated. No cytotoxic effects were observed by the unloaded drug delivery 
system, which was a very crucial result. Both, unloaded and mTHPC-loaded modified 
AuNP accumulated to the cells and some of both nanoparticles were found inside of 
the cells. The key result was the observation of the strong mTHPC release into the 
cytoplasm by the modified AuNP carriers. Following phototoxicity tests resulted in a 
delayed phototoxicity compared to the free drug. A great advantage of the mTHPC-
loaded mAuNP was their strongly reduced dark toxicity in comparison to the free 
mTHPC. All in all, the modified AuNP can be considered as promising drug delivery 
system for water insoluble photosensitizers. 
Nevertheless, further improvements of the drug delivery system could be necessary 
especially regarding its tumor specificity. To reach this aim, the attachment of cell 
  Conclusion 
type specific ligands, such as antibodies to the drug carrier surface is an auspicious 
way. Furthermore, it is indispensable to learn more about the distribution, uptake or 
efficiency of the drug delivery system in the animal experiment if the administration of 
the carrier system is the aim. 
 
 
8 List of Abbreviations 
 
ABC area between the curves 
AUC area under the curve 
AuNP gold nanoparticle/s 
BrdU 5-bromo-2-deoxyuridine 
BSE backscattered electrons 
C carbon 
CS carrier system 
DDS drug delivery system 
DNA deoxyribonucleic acid 
EPR enhanced permeability and retention  
ESS 4-ethyl(styrene sulfonate) sodium salt = monomer unit of PSS 
EtOH ethanol 
FCS fetal calf serum 
H hydrogen 
HT29 human colon carcinoma cell line 
ISC intersystem crossing 
LbL layer-by-layer 
LDH lactate dehydrogenase 
mAuNP modified gold nanoparticle/s 
mTHPC 5,10,15,20-tetrakis(3-hydroxyphenyl)chlorin 
mTHPP 5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrin 
N nitrogen 
NCI National Cancer Institute 
NNI National Nanotechnology Initiative 
NP nanoparticles 
PAH poly(allylamine hydrochloride) 
PDT photodynamic therapy 
PE polyelectrolyte 
PS photosensitizer 
PSS poly(styrene sulfonate) sodium salt 
QY singlet oxygen quantum yield 
S sulfur 
SD standard deviation 
SE secondary electrons 
SEM scanning electron microscopy 
TEM transmission electron microscopy 
UV/vis ultraviolet/visible 
WST-1 water soluble tetrazolium (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium) 
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